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Abstract 
Cigarette smoke (CS) has many damaging effects on the body, and the chronic 
inhalation of cigarette smoke can change immunological functions through impact 
on both innate and adaptive immunity. The incidences of many diseases are affected 
by the adverse effects of cigarette smoke on the immune system, and the induction 
of an inflammatory response, which affects several tissues and organs. On this 
basis, a comparison of smokers and non-smokers immunoglobulin levels could 
provide valuable insights into the mechanisms of smoking related diseases. 
Although the effects of cigarette smoking on humoral and cellular immunity have 
been investigated previously, the results have varied between the studies, and 
therefore more research is still required.  
The aim of this study was to determine whether the levels of immunoglobulin (Ig) 
isotypes are different in the serum and saliva of non-smoking individuals compared 
to smoking individuals. An examination of serum and saliva would provide 
information on the effects of cigarette smoke systemically and in the oral mucosa, 
respectively. The effects of cigarette smoke extract on B-cell secretions were also 
examined to establish whether cigarette smoke components can have direct effects 
on immunoglobulin production by B cells. In order to determine Ig isotype levels, 
antibody microarray techniques were established and calibrated for determining the 
sample concentrations of IgM, IgG, IgA and IgD. The results showed that smoking 
has different effects on systemic and salivary immunoglobulin levels. In the serum, 
smokers had decreased levels of IgG and IgD, but increased IgM and IgA levels 
compared to non-smokers. However, in the saliva smokers had decreased levels of 
IgG, IgD, and IgM, whereas there were increased levels of IgA in smokers’ saliva. 
As CS has been found to influence the serum and salivary levels of Ig isotypes ex-
vivo, the mechanisms underlying these effects were investigated in vitro to 
determine whether the changes were as a result of a direct effect of the CS on B-
cells. This study has shown that CS had deleterious effects on the production and 
the levels, of Ig isotypes. These results support the concept that CS is related to 
diseases, and more research is necessary in this field. 
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Chapter 1                                                                                   General Introduction 
1 
 
1. General Introduction 
Smoking is considered as one of the crucial causes of morbidity and mortality 
worldwide, and there are numerous diseases which are correlated with smoking 
habits such as cardiovascular disease, and lung disease [1-3]. It is known that 
cigarette smoke has many toxic components such as nicotine, and these components 
have immunomodulatory properties [4, 5]. Studies have shown that nicotine for 
example can cause inhibition of the innate and the adaptive immune system; 
immunological irregularities and suppression of the immune system which could 
play a role in the incidence of certain conditions and diseases [6]. Also, cigarette 
smoke has been shown to decrease the function of immunocompetent cells in 
experimental animals both in vitro and in vivo, and it has been shown that smokers 
have reduced quantities of serum immunoglobulins and an altered antibody 
response to the influenza virus after natural infection and vaccination [5, 7]. 
Although, smoking has been shown to change the immunological response to 
antigens; for example in the pathogenesis of allergic alveolitis and respiratory 
infection, more research is required to fully evaluate the biological effects of 
cigarette smoke, especially nicotine, on the immune system [5, 8].  
1.1. Innate immunity 
Innate immunity refers to the non-specific defence mechanisms that include 
physical barriers such as the skin, chemicals, and immune cells that attack foreign 
materials in the body. It works immediately or within hours of invaders attacking 
the body.  The major roles of innate immunity involve it acting as a physical and 
chemical barrier to infectious agents; the dead cellular layer of the skin acts as a 
barrier to infection, and the mucous membranes secrete enzymes that can destroy 
bacteria, produce mucus that entraps microbes and there are cells expressing cilia 
that filter pathogens. The innate immune response causes recruitment of immune 
cells to places of infection through release of chemical factors called cytokines, 
stimulation of the complement cascade to help eliminate bacteria, and assisting in 
the identification and removal of foreign substances that exist in organs, tissues, the 
blood and lymph. Additionally, it can activate the adaptive immune system through 
the presentation of antigens by antigen presenting cells (APC) and phagocytes such 
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as neutrophils which phagocytize bacteria; eosinophils which secrete enzymes to 
kill parasitic worms, and macrophages which are the main tissue phagocytic cells 
against many pathogens [9-11]. 
1.2.  Adaptive immunity 
The B and T lymphocytes are generated from active lymphoid stem cells; the main 
site of B cell production is the liver in the foetus and the bone marrow in adults, 
whereas T-cells are produced from bone-marrow pre-T cells that migrate to the 
thymus for development and maturation (Figure 1.1). The adaptive immunity is 
activated when the innate immunity alone fails in eliminating the pathogen. Antigen 
presenting cells, such as dendritic cells, B cells and macrophages, engulf the 
pathogen, process it and present it in association with major histocompatibility 
complex molecules (MHC), which interact with and activate the antigen-specific T 
lymphocytes triggering the adaptive immune response. Adaptive immunity is more 
effective, specific and has a “memory” that creates a more efficient response in case 
re-infection happens in the future; its response can be divided into the cell-mediated 
immune response and the antibody-mediated (humoral) immune response [12, 13]. 
1.2.1. Cell-Mediated immune response 
Cell-mediated immunity includes the activity of T cells, macrophages and natural 
killer cells, which all have specific roles (Table 1.1). 
1.2.1.1. T-lymphocytes  
In the thymus, T cells differentiate into two different forms: T-helper (Th-cell), 
which express cell-surface cluster of differentiation CD4 proteins, and T-cytotoxic 
cell (Tc-cell) which have CD8 cell-surface proteins. The main function of CD4+ 
and CD8+ is to regulate which molecules can interact with the T-cell. T-cells 
recognize the pathogens through APCs; APCs that have MHC class II can only bind 
with CD4+ on the surface of Th-cells, while APCs with MHC class I can only bind 
with CD8+ on the surface of Tc-cells. Therefore, APCs are highly specific and 
depend on the type of MHC presented [13].  
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Figure 1.1: Stem cell development.  
Stem cells develop in bone marrow or in foetal liver; then migrate to bone marrow 
and thymus. Bone marrow is the major site for B cells production, and thymus is 
the major site for T cell production.  
 
Table 1.1: Details of how the cell-mediated immune response involves T cells, 
macrophages and natural killer cells.                                                                                       
Cell Function 
T helper (Th1) 
Activates cells related to cell-mediated immunity – 
macrophages, Tc cells and natural killer cells 
T helper (Th2) Stimulates production of eosinophils, IgM and IgE 
Cytotoxic T lymphocyte (CTL) Destroys target cells 
T regulatory (T reg) cell 
Regulates immune response and helps maintain 
tolerance 
Activated Macrophage Enhances phagocytic activity, attacks cancer cells 
Natural Killer (NK) cell 
Attacks and destroys target cells; participates in 
antibody-dependent cell-mediated cytotoxic 
Stem cells develop 
in bone marrow or 
on fetal liver  
Red bone 
marrow of 
adult 
Thymus 
Differentiate to B cells  
in adult red bone marrow 
Differentiate to T cells  
in Thymus 
Migrate to lymphoid tissues such as spleen,  
but specially lymph node  
B cells T cells 
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1.2.1.1.1. T-helper cells (Th) 
The activation of Th cells occurs through three steps: the direct interaction between 
the Th cells and APCs stimulate activation and differentiation of Th, and then 
secretion of cytokines. These results in activation of B cells to plasma cells or T 
cells to effector cells dependent on the types of cytokines involved. To start 
differentiation of Th cells, APCs secrete IL-1, which stimulates the Th cells to 
secrete interleukin 2 (IL-2) that has an autocrine (self-stimulating) function and 
causes further proliferation and maturation of Th cells to functional helper cells. At 
this stage, Th cells can differentiate into different subsets Th1, Th2 or Th17 cells, 
which differ in the types of cytokines that they produce. Th1 cells can help in 
developing cell-mediated immunity, Th2 cells work toward developing humoral 
immunity, and Th17 cells help in the stimulation of macrophages [12]. 
Additionally, the immune response may change between activating humoral or cell-
mediated immunity because Th1 cells can inhibit the activity of Th2 cells and 
vice versa. For example, antigens resulting from viral, bacterial pathogens or cancer 
cells appear to produce a larger amount of Th1 cells compared to Th2cells, 
whereas antigens resulting from multicellular parasites and allergens may lead to 
an increased Th2 cell production. However, several antigens such as the tetanus 
vaccine can induce humoral and cell-mediated responses simultaneously [14]. As 
the Th cells are essential for the production of the humoral and cellular immune 
responses, the destruction of these cells by some viruses, such as the human 
immunodeficiency virus (HIV), leads to life-threatening diseases [12, 15, 16]. 
1.2.1.1.2. T-cytotoxic cells (Tc) 
Cytotoxic T cells (CTL) are activated when the T-cell-receptor (TCR) of a CD8+ 
Tc cell recognizes a cell which was infected with a virus or any other intracellular 
pathogen that is presented through MHC class I molecules. There are two ways of 
activation, the first occurs through CD4+ Th1 cells which recognize the virus 
through MHC class II and secrete IL2 that binds to the Tc cells and activates them 
to attack the pathogen infected cells; the other activation occurs when dendritic cells 
present the antigen by MHC class I and that leads to recognition of the pathogen by 
CD8+ Tc-cells (Figure 1.2). Once activated the number of Tc cells increases and 
they travel throughout the body to search for antigen-positive cells [17].    
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Figure 1.2: Overview of the adaptive immune response after antigen 
recognition.  
Infected cells present antigen peptides by MHC I molecules on the plasma 
membrane. The peptide-MHC I complex is recognized by precursor cytotoxic 
CD8+ T lymphocytes (pCTLs). pCTLs are activated by two pathways: in the first 
pathway Th1 cells, induced by antigen presenting cells, produce IL-2, interferon-
gamma (IFN-γ), and TNF-α. In the second pathway, dendritic cells present B7-
CD28. This results in activation and differentiation of the precursor CTLs into 
memory or effector CTLs. Effector CTLs can directly kill infected cells by the 
production of perforins and granzymes. Also, activated Th2 cells stimulated by 
antigen presenting cells produce B cell stimulating cytokines (including IL-4, IL-5, 
IL-6, IL-10, TGF−β) that activate naive B cells. This causes B cell differentiation 
into memory B cells and plasma cells that generate IgG, IgA, IgE antibodies that 
block more virus infection. Ab: antibody, Ag: antigen, APC: Antigen Presenting 
Cell, DC: Dendritic Cell IL: Interleukin, TCR: T Cell Receptor, Th: CD4+ T helper 
cells. 
 
IL-4, IL-5 
IL-6, IL-10 
TGF-B 
Ag 
B-cell Infected cell 
MHCI+Ag 
CD8 TCR 
IL-2 
IL-12 
INF-γ 
TNF-α 
MHC II+Ag 
CD4 TCR 
Memory B-cell Plasma cell 
B7 
CD28 
Effector CTL 
Antibodies production 
MHC II+Ag 
CD4 TCR 
CD28 
Th1-cell	 Th0-cell 
Th2-cell 
Chapter 1                                                                                   General Introduction 
6 
 
The cytotoxicity of CTL and the killing of infected cells occurs in three steps – 
formation of the CTL-target cell conjugate, entry of granzymes into the target cell 
via a perforin channel, and finally apoptosis of the target cell [12]. To form a 
conjugate the TCR-CD3 complex binds to the antigen which was presented by 
MHC class I and it forms a complex with MHC class I; other accessory proteins are 
needed to stabilize this interaction, therefore the CD8+ molecule and Fas ligand on 
the Tc cell interact with their respective receptors on the target cell. Then, the 
granules in the CTL begin moving through the cytoplasm to the conjugation zone. 
TCL are compressed and form an immunological synapse area between the two 
cells. 
There are two mechanisms that have been shown to kill the target cells – perforin 
and granzyme-mediated or Fas-mediated apoptosis [12, 18, 19]. 
1.2.1.1.2.1. Perforin and granzyme mediated apoptosis   
Perforin proteins are released from Tc granules by exocytosis and, in the presence 
of calcium ions, polymerize to form a round hole of 16 nm diameter. Perforins have 
a domain that can interact with cell membranes of the target cells. There is some 
evidence to suggest that granzymes that are also released from the granules pass 
through the perforin hole, but other research has suggested that granzymes are 
internalized by receptor mediated endocytosis, and then they are released into the 
cytosol by a signal delivered by the perforin. There are two important granzyme 
types – A and B; granzyme A generates apoptosis via a caspase independent 
pathway. Since it is translocated to the mitochondrial membrane cytochrome C is 
produced, which binds and activates intracellular receptor proteins, which results 
in activation of caspases. The caspases activate deoxyribonucleases (CAD) that 
cause DNA fragments, and each DNA fragment is surrounded by cytoplasm making 
apoptotic blebs [12, 18, 20] (Figure 1.3).  
1.2.1.1.2.2. FAS-mediated apoptosis 
CTLs express Fas ligand (FasL) that binds to target cell Fas receptors, this activates 
caspases-8, which in turn activates caspases-3, 6 and 7. Finally, calcium dependent 
apoptosis occurs [21] (Figure 1.3).   
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1.2.1.1.3. T-regulatory (Treg) cells  
These are a group of T cells that regulate the immune response by suppression. 
They express CD4+, and bind to antigens through MHC class II molecules and their 
differentiation is controlled by various cytokines, primarily TGF-β (transforming 
growth factor-beta) and IL-2. Treg cells produce very high levels of TGF-β and IL-
10, and other immunosuppressive cytokines, which generally reduce the activity of 
Th1 and Th2 cells by suppressing antigen identification and Th cell proliferation 
[12, 22]. 
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Figure 1.3: Effector cytotoxic T cells killing of target cells by two strategies.  
(A) Perforin and granzyme mediated apoptosis; the cytotoxic T cell (TC) releases 
perforin and proteolytic enzymes onto the surface of an infected target cell by 
localized exocytosis. The presence of high concentrations of Ca2+ in the 
extracellular fluid leads to the accumulation of perforin in transmembrane channels 
and this permits the proteolytic enzymes to arrive into the cytosol of the target cell. 
Then, granzyme B cleaves and triggers specific procaspases, causing activation of 
the proteolytic caspase cascade and apoptosis. (B) FAS-mediated apoptosis; the 
binding between the Fas ligand on the cytotoxic T cell surface and the Fas receptor 
protein on the surface of a target cell leads to activation of Tc cells. The Fas 
cytosolic tail includes a death domain, which, when activated, binds to adaptor 
proteins, which in turn triggers a particular procaspase (procaspase-8). Procaspase-
8 molecules then split one another to yield active caspase-8 molecules that start the 
proteolytic caspase cascade leading to apoptosis (This figure has been reproduced 
from figure 24-46 of Molecular Biology of the Cell “T cell and MHC proteins 
chapter”, reference number [17]). 
1.2.1.2. Macrophages 
Macrophages stimulate apoptosis through secretion of tumour necrosis factor 
(TNF). If the target cell is too large to be phagocytosed, the macrophage uses 
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“frustrated phagocytosis” which results in necrosis of the target cell and 
inflammation [9, 23]. 
1.2.1.3. NK cells                                                
NK cells are large granular lymphocytes containing perforin and granzymes in their 
cytoplasm, they are non-specific, and are involved in killing virally-infected cells 
and tumour cells [20]. They recognize their target cells in two ways: first, by linking 
to target cells via IgG antibodies that bind to Fc receptors on their surface (known 
as antibody-dependent cellular cytotoxicity). The second way is dependent on 
activating and inhibitory receptors expressed on their surface; the killer-activating 
receptors bind to various molecules, such as carbohydrate ligands, on other cell 
surfaces and stimulate the killing process. Also, all nucleated cells have MHC class 
I molecules which bind to the killer-inhibitory receptors on the NK cell surface and 
inhibit cytotoxicity. NK cells can distinguish between infected and uninfected cells 
by the alteration and down of regulation of MHC class I molecules on some infected 
cells, and also on some cancer cells [24]. When NK cells are activated, they release 
perforins and granzymes that cause target cell apoptosis in a similar way to Tc cells. 
Also, NK cells can use Fas/Fas-ligand binding mechanisms to kill tumour and viral 
infected cells by apoptosis [9, 23]. 
1.2.2. Humoral-immune response (B-cells) 
The human body produces millions of clones of B cells that circulate in the blood 
and lymphatic system. B cells are created in the bone marrow and when they mature 
to express an IgM+ receptor on their surface they migrate to secondary lymphoid 
tissues, such as spleen and lymph nodes. Each B cell surface has a unique surface 
immunoglobulin (sIg) that recognizes and binds a specific antigen, which causes B 
cell activation, proliferation and maturation leading to secretion of free antibodies, 
which contain binding sites typical of those in the original sIg. Some of the B cells 
become memory cells that can identify the same antigen epitope when the body 
faces the same antigen, and therefore the humoral immune response will be more 
rapid and efficient in attacking the pathogens. The main functions of B cells are to 
produce antibodies, act as APCs, develop into memory B cells after interaction with 
an antigen, and release cytokines as signalling molecules to help to regulate the 
immune response.  
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The development of a B cell occurs in several steps, each step is characterised by 
alterations in the content of the genome at the antibody loci. Antibodies are made 
up of two identical light (L) chains and two identical heavy (H) chains, and the 
genes identifying them are located in the Variable (V) and Constant (C) regions 
(Figure 1.4) [12, 25] .   
 
Figure 1.4: Antibody structure. 
The antibody structure consists of two identical heavy chains, two identical light 
chains and has disulphide bridges between the chains. Heavy chains contain one 
variable domain and 3-4 constant domains that define the Ig isotypes, where γ 
(IgG), α (IgA) and δ (IgD) contain three constant domains, and the heavy chains μ 
(IgM) and ε (IgE) contain four constant domains. In mammals, there are only two 
types of light chain, λ and κ. A light chain contains two domains: one constant 
domain and one variable domain. The fragment crystallisable region (Fc region) is 
the part that combines with Fc receptors on cell surfaces. The Fc fragment is crucial 
for Fc receptor-mediated activity. The Fab region (fragment antigen binding) 
contains the variable domains that have hyper-variable regions: these have a high 
ratio of different amino acids within immunoglobulins specific for different antigen 
epitopes.  
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1.2.2.1. Sub-populations of B cells                                                                                      
1.2.2.1.1.  B-1 cells  
These are the first B cells that are created in the foetus, and in adults they are found 
mainly in the peritoneal and pleural cavities [26]. B-1 cells have been shown to work 
in the innate response; B-1 lymphocytes express (poly-specific) IgM in larger 
concentrations than IgG, they express little or no IgD, and they express CD5 
protein, which binds to CD27 to facilitate B cell-B cell interactions.  B-1 cells react 
weakly to protein antigens and more strongly to carbohydrates, there is no evidence 
for class switch and they secrete abundant antibodies of low affinity [12, 27].  
1.2.2.1.2.  B-2 cells  
These are formed in the re-population that happens in bone marrow. They express 
IgD as well as IgM on their surface, undergo class switching and have a greater 
affinity to antigens than B-1 cells [12, 28]. 
1.2.2.1.3.  MZ B cells  
These exist in the marginal zones of the spleen, in the subscapular sinus of lymph 
nodes, in the epithelium of tonsils and in Peyer’s patches. They have sIg and are 
implicated in innate/early adaptive immunity [12, 29-31].  
1.2.2.1.4.  Naïve B cells  
Naïve B cells express IgM and IgD. They are activated by two mechanisms, the 
first is dependent mainly on Th cells (T cell-dependent activation), and the second 
is not dependent on T-cells (T cell-independent activation) [12, 30, 32].  
1.2.2.1.5.  FO B cells  
Follicular (FO) B cells exist mainly in the germinal centre of lymph nodes. They 
are activated when they are exposed to Toll-like receptor (TLR) ligands and 
differentiate into short-lived plasma cells [12, 30]. 
1.2.2.1.6.  Memory B lymphocytes  
These cells are generated in lymphoid tissues after the activation and proliferation 
of B cells and they are located in the bone marrow, lymph nodes and spleen. They 
are long-lived, quickly stimulated and are prepared for a rapid reaction to a repeated 
exposure to an antigen [12, 30].  
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1.2.2.1.7.  Plasma cells  
These are terminally differentiated B cells that produce large amounts of antibodies 
against a specific antigen; they can be short-lived or long-lived [12, 31].  
1.2.2.2.  Stages of B cell development and differentiation 
 Before birth, B cell development takes place in the yolk sac, the foetal liver and 
foetal bone marrow, while after birth this occurs solely in the bone marrow. 
Differentiation of B cells can be classified into two phases, antigen independent 
differentiation and antigen dependent differentiation [31] (Figure 1.5).  
1.2.2.2.1. Phase I: Antigen independent differentiation   
In the bone marrow, the progenitor B cells (pro-B cell) express the adhesion 
molecule VLA-4, which contacts directly with the VCAM-1 ligand on stromal 
cells. This binding is used as a trigger for the production of IL7 from stromal cells 
that binds with IL7 receptors on the pro-B cells, inducing their development into 
precursor-B cells (pre-B cell) that then undergo proliferation. After proliferation 
the Ig genes are rearranged in an ordered fashion to generate the primary Ig 
repertoire [31, 33].  
In the Pro-B cell phase, the heavy chain diversity (D) and joining (J) gene segments 
undergo DJ gene arrangements followed by V region and VDH creation. Later, 
these cells differentiate into pre-B cells by completing the light chain gene re-
arrangements. The pre-B cells can then express membrane Ig with a surrogate light 
chain, which consists of V pre-B as a variable region and lambda 5 (λ5) instead of 
a constant region, and these become associated with Ig-α/ Ig-β heterodimers to form 
a pre-BCR (pre-B-cell receptors). These changes mean that pre-B cells produce 
IgM (μ chains), which are transiently expressed in association with two smaller 
polypeptide chains (V pre-B variable and λ5) (Figure 1.6) [34, 35].  
Multiple cell divisions occur which results in the production of immature B cells 
that contains functional BCR (immature naïve B cell). In these cells the variable 
region of the heavy chain consists of three segments, V, D, and J, and they are 
recombined randomly through the VDJ recombination process. Similar processes 
occur in the light chain, but there are only two segments at variable region V and J 
[35]. The formation of the BCR starts when the recombinase enzyme complex 
catalyses the fusion of one DH region gene to a JH region gene with the deletion of 
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the intermediate DNA sequences. The recombinase then joins one VH region gene 
to the rearranged DHJH gene. The enzyme terminal deoxynucleotidyl transferase 
(TdT) is expressed, adding random nucleotides to the sites of VHDHJH joining and 
enhancing the diversity of amino acid sequences. That pairs with an L chain and 
produces IgM. When the VHDHJH element is followed downstream by exons 
encoding the C region for the 𝛿 chain, it produces IgD. These events occur because 
of alternative RNA splicing. Finally, if the rearrangement of VH, DH, and JH 
elements yields an H chain transcript and encodes a functional H chain protein, this 
H chain is synthesized and pairs with 2 proteins (called 𝜆5 and VpreB), which act 
as a surrogate light chain, and results in the expression of a pre-BCR. Once a 
functional heavy chain is produced, the cell down-regulates the gene and initiates 
an L chain rearrangement. It first begins with a 𝜅 element and, if this rearrangement 
is unsuccessful, continues with a 𝜆 element. A V𝜅 element rearranges to a J𝜅 
element and produces a light chain, which, if it is functional, pairs with the H chain 
to make an immunoglobulin protein [36]. 
During maturation, if a B cell fails in any step it will die by apoptosis. Immature B 
cells leave the bone marrow and migrate to the spleen, where they complete their 
early development by differentiating into naïve mature B cells, which can be 
detected by the co-expression of IgD and IgM on the cell surface, follicular, or MZ 
B cells (Figure 1.7, 1.8) [12, 37]. This differentiation mechanism has been shown 
to include several enzymes and transcriptional factors.  
After differentiation, around 10 % of the B cells are lost and the remaining 90 %, 
which are mature B cells, migrate into secondary lymphoid organs where they 
become functional, with a half-life of between 3 days to 8 weeks, and they die by 
apoptosis in the absence of antigens [31, 37, 38]. 
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Figure 1.5: B cell differentiation in the bone marrow (BM) and periphery 
occurs in multiple steps.  
The antigen-independent steps are in the blue background and the antigen 
dependent steps are in the cream background. In BM, the primary phases of B cell 
development result in the formation of immature B cells, which leave the BM and 
move to the spleen. These cells are now called transitional 1 (T1) cells, which 
differentiate in to transitional 2 (T2) cells, and can continue their maturation to 
naïve or marginal zone (MZ) B cells. Naïve B cells leave the spleen and recirculate 
via secondary lymphoid organs and the blood. In the presence of an antigen, naïve 
B cells are activated and form germinal centres (GC). Cells with a high ability to 
bind to antigens are incorporated into the long-lived peripheral lymphocyte pool 
and are chosen to differentiate to memory B cells or long-lived plasma cells. 
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Figure 1.6: Membrane Ig in pre-B cells. 
Pre-B cells have a membrane Ig (mIg), which contains V pre-B as a variable region 
that is combined with surrogate light chain, containing lambda 5 (λ5) as a constant 
region. The mIg are associated with heterodimer Ig-α/ Ig-β.  
  
Figure 1.7: Stages of B cell differentiation.  
The co-expression of IgD and IgM on the cell surface identifies the naïve mature B 
cells and, in the germinal centre, B cells could express IgG or IgA or IgE depending 
on the Ag type and type of T cell help received (This figure has been adapted from 
reference number [39] ).  
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Figure 1. 8: B-cell development. 
At the pro-B stage DH join to JH, creating a DJH rearrangement. Then, at the pre-
B stage, VH joins to DJH which results in production of the complete VDJH 
rearrangement. If this VDJH is functional, the cell can develop into a mature B-cell 
that expresses surface IgM (IgM+). These cells are then able to enter the GCs where 
SHM and CSR occur, thus the cells become VH- mutated, and class-switched (e.g., 
IgA) memory B or plasma cells (This figure has been adapted from reference 
number [37]). 
1.2.2.2.2. Phase II: Antigen dependent differentiation  
In the secondary lymphoid organs, further differentiation of mature B cells occurs 
dependent on its exposure to an antigen. The activated-mature B cells migrate into 
the primary follicles of lymphatic tissues and ultimately mature into F0 or MZ B 
cells. The cell-cell interactions need the expression of membrane-bound LT𝛼/𝛽 
trimers and TNF, while T cell-dependent B cell differentiation needs the 
recruitment of CD40 (TNFRSF5) by CD40L on activated CD4+ T cells [12, 40]. 
CD30 (TNFRSF8) is expressed on activated B cells and has been found to be vital 
for effective memory B cell production, and CD27 is also involved in B cell 
memory development. After proliferation of B cells in germinal centres, the 
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primary immune response is mediated by short-lived plasma cells and long-lived 
plasma cells, and memory cells are generated for the secondary response [12, 25]. 
The specific mature B cells transform into plasma cells within 5 days. During this 
process, there is a progressive development of the ribosome and ER, where the 
content of RNA increases in the plasma cell that induces the protein synthesizing 
machinery and stimulates ER cisternae to become filled with antibody molecules, 
so the plasma cell can rapidly secrete them. 
The formation of antibodies is consistent with the theory of clonal selection, which 
was proposed by Nobel Laureates Frank MacFarlane Burnet and Peter Medawar 
[41]. Lymphoid organs generate many B cells with different surface receptors, and 
the basis of the theory depends on a particular antigen epitope binding with the 
appropriate B-cell receptor (BCR), leading to the activation of a selected single B 
cell, which becomes an enlarged immunoblast cell and undergoes division and 
clonal selection and, therefore, many clones of activated plasma cells are produced 
[12]. 
1.2.2.3. B cell transcription factors                                                
Development of the B cell lineage is dependent on bone marrow stromal cells, 
which generate IL-7 and many other factors such as PU-1, E2A, early B cell factor 
1, paired box gene 5 (PAX), and interferon regulatory factor 8 (IRF8). Pax5 is one 
of the most critical transcription factors as it restricts the developmental potential 
of lymphoid progenitors to the B cell pathway through blocking B-lineage-
inappropriate genes, and it simultaneously stimulates B cell development through 
upregulating B-lymphoid- specific genes. Studies have shown that Pax5 regulates 
gene transcription via chromatin remodelling, histone modification, and recruiting 
basal transcription factor complexes to their target genes [39]. Moreover, Pax5 
contributes to the variety of the antibody repertoire through regulating VH-DJH 
recombination and it stimulates the contraction of the Ig heavy-chain locus in pro-
B cells. Also, essentially all mature B cell types depend on Pax5 for their 
differentiation and function, and. therefore Pax5 regulates the identity of B 
lymphocytes through B cell development. Accordingly, conditional damage of 
Pax5 permits mature B cells from peripheral lymphoid organs to develop into 
functional T cells in the thymus via differentiation to uncommitted progenitors in 
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the bone marrow. Pax5 has also been associated with certain diseases involving 
human B cell malignancies [25]. 
1.2.2.4. Surface markers 
In the pro-B cell period, the B cells express CD45R, Ig-α/ Ig-β, CD19, CD43 and 
CD24 and c-kit surface molecules. In the pre-B cell period, B cells express the same 
molecules, except c-kit and CD43, and they start to express CD25, and the α-chain 
of IL2 receptor [38, 42, 43].  
1.2.2.5. Activation of B cells  
The activation of B cell starts when the receptor recognizes and binds to an antigen. 
Activation of B cells occurs through two pathways, T-cell independent activation 
in response to carbohydrate or lipid antigens, and T-cell dependent activation in 
response to protein antigens (Figure 1.2) [11]. 
1.2.2.5.1. T-cell independent activation 
The T-cell independent antigens can activate B cells without T-cell help; in the case 
of TI-1 type antigens, such as LPS (lipopolysaccharide), the first signal occurs 
through binding between BCR and antigens, and the second signal is produced by 
Toll-like receptors (TLR4). For the TI-2 type antigens, carbohydrates on the surface 
of bacteria have repeated epitopes that can react with, and crosslink, a large number 
of BCRs; the B cells can then proliferate without Th cells. Since there is no CD40 
signal or cytokines involved, the antibody response is weak, the cells cannot 
undergo isotype switching, and they induce poor B cell memory [11, 12].  
1.2.2.5.2. T cell dependent activation  
T cell dependent activation of B cells needs two signals; the first occurs when an 
antigen binds and produces clustering of the BCR. The second signal occurs when 
the CD40L protein on the surface of an activated T helper cell binds the CD40 
protein on B cell surface. Once a B cell binds the antigen, the antigen molecule is 
taken into the cell through endocytosis and is then represented on the cell surface 
by MHC class II molecules. This process means the B cell is sensitized and can 
bind with a Th cell. The Th cell is activated through binding to antigen-MHC class 
II complexes on the surface of the B cell, and this results in cytokine secretion, 
which stimulates the B cell to divide and produce thousands of identical plasma or 
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memory B cells. These plasma cells are responsible for secreting antibodies against 
these antigens, while the memory B cells stay inactive at this time, and later when 
the body is re-exposed to the same antigen, they will divide into plasma cells which 
are able rapidly to secrete antibodies [11]. 
1.2.2.6. Role of cytokines in B cell maturation and activation 
 The cytokine IL-7 is important in the development of B cells; it conducts numerous 
significant functions including assisting in the specification and commitment of 
cells to the B cell lineage, the proliferation of B cell progenitors, and maturation of 
pro-B to pre-B cells. During B lymphopoiesis, the regulation and modulation of the 
IL-7 receptor (IL-7R) signalling is critical as extreme or poor IL-7R signalling 
causes unusual or reduced development of B cells [44]. Studies have shown that 
IL-7 works with the transcription factors E2A, EBF, Pax-5, and others to control B 
cell commitment.  IL-7 also works to control Ig rearrangement by modifying FoxO 
protein activation and Rag enhancer activity. Therefore, the appropriate IL-7 
signals are transmitted to permit the commitment and development of B cells [44].  
CD4+ T cells also secrete cytokines that are responsible for controlling B cell 
proliferation and differentiation. In delayed-type hypersensitivity reactions and 
cell-mediated immunity, naïve CD4+ T cells, in the presence of IL-12 and IFN-γ, 
develop into the Th1 subset. Subsequently, the Th1 cells stimulate the activation of 
the cell-mediated immune response, and therefore, CD8+ T cells, NK cells and 
macrophages are activated. During the detection and destruction of certain viruses, 
extracellular bacteria, soluble toxins, multicellular parasites and in allergies, Th2 
cells can produce type-2 cytokines (IL-13, IL-4, IL-5, IL-10). Studies have shown 
that IL-2 and IL-4 producing cells activate B cells toward entry into M phase, and 
IL-4, IL-5, IL-6, and IL-13 signal B-cells to divide, differentiate and secrete 
antibodies. IL-4 and IL-10 stimulate the humoral response; they stimulate the 
growth and activation of mast cells and eosinophils, and switch antibody synthesis 
to IgE. Moreover, they suppress the activation of macrophages, T-cell proliferation, 
and the production of pro-inflammatory cytokines; they are also known as anti-
inflammatory cytokines.  Studies have also shown that Th1 cytokines can suppress 
the function of the Th2 subset. The type of cytokines that are produced from 
activated T cells can determine antibody class switching: for example, if a Th cell 
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produces IL4, then the B cell will switch to IgE production, whereas if IFN- γ is 
produced, then the B cell will switch to IgG production [12, 45, 46].  
1.2.2.7. B cell class switching  
Naïve B cells express IgM in a cell surface bound form; after maturation it can 
express both IgM and IgD, and engagement with antigens by sIg initiates the cell 
to differentiate into cells that produce antibodies, which are called plasma cells. If 
an antigen activates a B cell and there is also stimulation of CD40 by CD40-ligand 
on a helper T cell, the B cell class switching starts to produce different isotypes of 
the antibodies. During the Ig class switching, the change occurs in the constant 
region of the heavy chain, while the variable regions remain the same, and that does 
not affect the specificity for the antigen. These changes take place in the constant 
region genes on chromosome 14, where there is deletion of the -chain constant 
domain DNA and association with one of the other constant region genes, which 
produces other isotypes depending on the type of constant region added. This 
process enables a B cell to produce different isotypes of antibodies necessary to 
fight the relevant antigens [25, 31].  
1.2.2.8. Antigen-antibody binding 
The microbes involved in attacking the body usually contain multiple small or large 
antigens on their surface; the area where this antigen is bound to an antibody is 
called an epitope or an antigenic determinant, and the corresponding area on the 
antibody is called an antigen binding site or paratope. The folding of heavy and 
light chain complementarity determining regions (CDRs) within the variable 
regions creates the specific antigen-binding site; an antigen-binding site is formed 
from 6 CDRs, half of them are generated from the heavy chain and half of them 
from the light chain. The antibody specificity depends on the shape and the 
chemical composition of the amino acids that compose the CDRs, therefore the 
antigen epitope that has a complementary structure and chemistry can fit strongly 
with that site, binding with non-covalent bonds [11]. The two heavy and light chains 
of a single immunoglobulin are identical; therefore, they bind to identical antigen 
epitopes. The multiplicity of binding sites is called valency; IgG, IgE and IgD have 
a valency of two, secretory IgA has a valency of 4, and IgM has a valency of 10.  
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Each BCR has three components: a membrane immunoglobulin (mIg) associated 
with two accessory proteins, the heterodimers Igα and Igβ.  The C-terminus of the 
heavy chain that crosses into the cytoplasm of the cell is very short – only three 
amino acids in length – which is insufficient to activate a signalling response. The 
Fab region is extracellular and plays a role in ligand attachment, whereas the Fc 
region binds non-covalently with Igα-Igβ, which have long cytoplasmic tails that 
consist of 61 and 48 amino acids, respectively. Both chains include an 18-residue 
long motif in their cytoplasm regions known as the immunoreceptor tyrosine based 
activation motif (ITAM); when an antigen binds to the BCR, the tyrosine residues 
in the ITAMs become phosphorylated, which means that certain SH2 domains 
existing in different proteins can recognize them. Therefore, phosphorylated 
ITAMs have the ability to recruit molecules that include certain SH2 domains to 
induce signalling (Figure 1.9) [47]. 
 
 
Figure 1.9:The interaction between Ag and B cell surface antigen receptor.  
The antibody has a paratope site, which can interact with the specific antigen at the 
epitope site. ITAM become phosphorylated to induce signalling pathway 
activation; ITAM is immunoreceptor tyrosine based activation motif.  
The interaction between Ag and B cell surface receptor  
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1.2.2.9. Immunoglobulins (Ig) 
Secreted Igs are a group of glycoprotein molecules synthesised by B-lymphocytes 
and plasma cells and found in the serum, body fluids and tissues; they are also 
known as antibodies. When an antibody is digested with the enzyme papain, its 
molecular structure is divided into three parts, two identical parts called Fab 
fragments that contain the antigen-binding site and determine the specificity of 
antibody, and the third fragment is the Fc region, which stands for ‘fragment 
crystallisable’ because this region was found to form crystals when separated from 
the Fab regions.  The Fc region determines all the biological functions of an 
antibody and determines its class. The antibody is composed of four polypeptide 
chains: two heavy chains and two light chains; the light and heavy chain loci are 
each composed of a sequence of V gene elements, followed by some D segments 
(for the heavy chain gene only), J segments, and C exons. Heavy chains (H) are 
made up from 4 segments (VH, D, JH, and CH), and light chains (L) are made from 
3 segments (VL, JL, and CL) (Figure 1.10). The genes for the 9 different heavy 
chain types (IgM, IgD, IgG1, 2,3 and 4, IgA1and 2, and IgE) are situated on 
chromosome 14 and those for the 2 light chain types (𝜅 or 𝜆) are located on 
chromosome 2 and 22, respectively [45].  
Heavy chains consist of 440-550 amino acids whereas light chains consist of only 
220 amino acid residues, each chain contains two types of domains – variable and 
constant domains. The H chain constant regions form the Fc domain of the molecule 
and are responsible for most of the effector functions of the Ig molecule (Figure 
1.10). Both variable domains contain “hypervariable” regions or CDRs, which 
identify and bind to specific antigens. The type of heavy chain determines the 
immunoglobulin isotype, and based on the structural and antigenic properties, the 
Igs can be divided into five main classes, IgM, IgG, IgA, IgE and IgD. IgG and IgA 
classes can be further divided into subclasses based on differences in their amino 
acid sequences in the H chains, but the carboxyl terminal portions are constant in 
each subclass of antibody [11, 48]. Overall the different structures of these Igs give 
them different properties (Table 1.2). 
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Figure 1.10: Schematic illustration of the immunoglobulins H and L chain 
modules.  
Each light and heavy chain locus consists of a series of V (variable) gene elements, 
followed by several D (diversity) segments (for the heavy chain gene only), some 
J (joining) segments, and C (constant region) exons. H chains are composed of 4 
segments (VH, D, JH, and CH); L chains are composed of 3 segments (VL, JL, and 
CL) (This figure has been reproduced from reference number [36]). 
1.2.2.9.1. Immunoglobulin G (IgG) 
IgG contains gamma heavy chains, and it is the most abundant antibody in the blood 
as it accounts for 75 % of the total serum antibodies. Based on the structural, 
antigenic and functional differences in the heavy chain constant regions – CH1, CH2 
, CH3 and particularly the hinge region – IgG is divided into four subclasses IgG 1, 
2, 3, and 4, with IgG1 being the most abundant [49]. IgG is a monomeric antibody 
that contains two antigen binding sites and it is particularly important in secondary 
immune responses. It can cross the placenta from the maternal blood and provide 
the foetus with immunity. Due to differences in the CH domain, there are 
differences in flexibility and functional activity between IgG subclasses. Generally, 
IgG1 and IgG3 are produced in response to protein antigens, whereas 
polysaccharide antigens induce IgG2 and IgG4. In addition, IgG contributes 
directly to an immune response as in neutralization of toxins and viruses, and 
triggering the complement cascade is the main way to clear the opsonized 
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pathogens [49]. There are two ways for IgG to interact with the immune cells; either 
through direct cytophilic interaction with macrophages, which is independent of the 
F(ab) region of the antibody and requires only Fc interactions. The other 
mechanism involves specific Fc receptors (FcγRs), which trigger effector responses 
such as macrophage phagocytosis, NK cell ADCC, and neutrophil activation. 
FcγRs are characterised by the existence of an ITAM motif, either intrinsic to the 
receptor, as in the case of the human FcγRIIA (a receptor not found in the mouse), 
or more frequently, as part of a subunit  associated with the γ chain, as in FcγRI and 
Fcγ RIIIA, receptors preserved between mouse and human. Moreover, human 
neutrophils have a specific receptor, FcγRIIIB that binds IgG immune complexes 
without generating activation. Cross-linking of the ligand binding extracellular 
domain leads to tyrosine phosphorylation of the ITAM by members of the src kinase 
family, followed by recruitment of SH2 containing signalling molecules, which 
interact the phosphorylated ITAM, most particularly the syk kinase family of 
molecules. The cell type which is activated by the Fc receptor determines the type 
of kinases that are involved in these signalling pathways [50] .  
1.2.2.9.2. Immunoglobulin M (IgM) 
IgM contains mu heavy chains, it forms a pentamer with a polypeptide chain called 
the J chain, and it contains 10 antigen-binding sites. It is the first antibody formed 
during the immune response, and it is a monomer when it acts as an antigen receptor 
on the surface of B-cells [41]. IgM accounts for approximately 5-10 % of the total 
serum antibodies and is located mainly in the bloodstream rather than other fluids. 
IgM is produced in the primary immune response and is commonly used to 
diagnose acute exposure to a pathogen. It not only participates in the first line of 
defence, but also plays an important role in immune regulation [49, 51]. The 
pentamer structure helps IgM to opsonize antigens for destruction and for fixation 
of complement. 
1.2.2.9.3. Immunoglobulin A (IgA) 
IgA contains alpha heavy chains, and constitutes about 10-15 % of serum 
antibodies, but it is highly expressed in body secretions such as saliva, mucus, tears, 
gastrointestinal, respiratory and genitourinary tracts and milk where it is called 
secretory IgA (sIgA); IgA makes up to 50 % of total protein in colostrum “first milk 
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for neonates”. In serum, IgA is a monomer and its levels tend to be higher than the 
IgM levels, but lower than IgG levels. However, at mucosal surfaces and in 
secretions, IgA levels are much higher than IgG levels, and the IgA has a dimer 
structure where it binds to a J-chain and another polypeptide chain called a secretory 
piece (derived by cleavage of the poly-Ig receptor that transports IgA across 
mucosal epithelial cells) [42]. Thus, IgA has an important role in protecting internal 
body surfaces that are exposed to the environment, where it blocks the attachment 
of bacteria or viruses to mucous membranes. IgA is classified into two subclasses 
according to differences in the structure and mainly in hinge regions, IgA1 and 
IgA2; the hinge region in IgA1 is longer than that in IgA2, therefore IgA1 is more 
sensitive to bacterial proteases, thus IgA2 predominates in several mucosal 
secretions. IgA is critical for protecting mucosal surfaces by attacking bacteria and 
viruses [49]. 
IgA interacts with a variety of receptors existent on different cell types and produces 
different outcomes. The poly-Ig receptor (pIgR) plays an important role on 
epithelial cells to transport IgA into mucosal secretions, as discussed previously. 
Another main receptor is FcαRI, which has a variety of roles to assist in removing 
pathogenic attackers. All these receptors demonstrate specificity for the α-heavy 
chain of IgA, while some, e.g. pIgR and Fcα/μR, also associate with other 
immunoglobulin isotypes. FcαRI, is a member of a family of Fc receptors included 
within the much bigger immunoglobulin gene superfamily [52, 53], but it has vital 
differences from the other Fc receptors in this group. Its gene is located in the 
leukocyte receptor cluster near to the killer cell immunoglobulin-like receptors and 
leukocyte immunoglobulin-like receptors on chromosome 19, contrasting to IgG-
specific FcγR and the IgE-specific FcεRI, which are clustered on chromosome 1. It 
is expressed on neutrophils, monocytes, eosinophils, platelets and some 
macrophages and dendritic cells. In addition, it is expressed on Kupffer cells in the 
liver where it has a role in mediating phagocytosis of pathogens that are present in 
the blood and have been opsonised by serum IgA [54]. Moreover, human FcαRI 
binds equally well to human IgA1 and IgA2 – both serum IgA and secretory IgA – 
although the effects may be different. FcαRI is a transmembrane glycoprotein with 
two immunoglobulin-like extracellular domains and a short cytoplasmic region that 
lacks any known signalling motifs, it associates with FcR-γ chain; also, some FcαRI 
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do not associate with FcR-γ chain dimer but are still able to bind IgA and 
endocytose IgA immune complexes [52, 55]. There are other receptors such as 
Fcα/μR, which interacts only with polymeric forms of IgA and IgM [52, 56]; and 
transferrin receptor (TfR) also can bind with IgA.  
1.2.2.9.4. Immunoglobulin D (IgD) 
IgD contains delta heavy chains, constitutes only 0.2 % of serum antibodies, and it 
is found on the surface of B-lymphocytes along with monomeric IgM, where it can 
act as a B-cell receptor that may regulate the activation and suppression of B-
lymphocytes. It has been found that during B-cell ontogeny, IgM and IgD are the 
first antibody isotypes expressed during the primary adaptive immune response, 
and after leaving the bone marrow B cells express surface IgM and IgD with the 
same specificity, but they are created through different splicing of a pre-messenger 
RNA. In humans, some B-cells class-switch from IgM to IgD, and in the case of 
IgM deficiency, IgD can be used to replace its function [57, 58]. 
IgD is found in serum, and in human secretions such as human nasal and 
cerebrospinal fluids, and also in the amniotic fluid of pregnant women where its 
concentration gradually increases during the first half of gestation [58-60]. IgD is 
often observed as a predominantly mucosal Ig isotype due to the fact that the upper 
aero-digestive mucosa is a better localization of IgD-producing B cells. Also, the 
presence of IgD, as well as IgD producing B-cells, in the circulation and in upper 
aero-digestive mucosa-associated lymphoid tissues (MALTs) indicates that IgD 
undertakes its immunological functions systemically and in mucosal areas. Secreted 
IgD can attack many pathogenic microorganisms in the upper aero-digestive 
mucosa; studies have shown that, during various infections, the number of IgD-
producing B cells is greatly increased in the upper aero-digestive mucosa in IgA 
deficient patients and serum IgD levels increase. Therefore, in IgA deficiency, 
secreted IgD may provide mucosal protection [58, 61]. Rogenine et al. showed that 
the fractional catalytic rate of IgD was similar to that of IgA, and much higher than 
those of IgM and IgG, which indicates that IgD might be catabolized in similar 
ways as IgA, but in very different ways from IgM and IgG [62]. 
Cell-associated IgD includes transmembrane IgD, intracellular IgD and secreted 
IgD bound to various cell types; for example, crosslinking of IgD receptors on T-
cells was observed as a preventive mechanism for T-cell apoptosis. Also, some 
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myeloid cell types are able to bind secreted IgD; studies showed that, in healthy 
subjects, basophils rather than neutrophils or eosinophils appeared to express more 
surface IgD [58], but under certain pathological condition, such as skin allergies 
and inflammation, neutrophils and/or eosinophils can bind significant amounts of 
IgD [58, 63]. Studies of monocytes did not show any significant IgD binding [64]. 
Furthermore, IgD can acts as an immune-modulator that can promote the immune 
defence by activation of IgD-interacting cells in tissues, the production of activating 
factors consequently causes damage and inflammation of tissues. The levels of 
serum IgD increases in many chronic infections, which suggests there is an 
important role of IgD in these types of infections [58, 65]. 
1.2.2.9.5. Immunoglobulin E (IgE) 
IgE contains epsilon heavy chains, it is a monomer, it has two antigen binding sites 
and it constitutes only about 0.002 % of the total serum antibodies. IgE binds 
strongly to basophils and mast cells via its Fc region, it is important during allergic 
responses, and it protects external mucosal surfaces by promoting inflammation 
that enables IgG, complement and leucocytes to enter the tissue, as well as causing 
removal of microbial toxins through coughing, sneezing and vomiting [61]. IgE is 
associated with hypersensitivity and allergic reactions, as well as the response to 
parasitic worm infections. It has high affinity to bind FcRI, which is expressed on 
mast cells, basophils and eosinophils. Recently, anti-IgE antibodies (e.g. the 
humanised monoclonal antibody omalizumab) have been used to treat allergy and 
asthma; these antibodies bind to free IgE and B-cell surface IgE, but not IgE bound 
to FcR since the latter could promote degranulation and inflammatory mediator 
release [49]. 
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Table 1.2: Summary of the classes of immunoglobulins [66]. 
 
     IgG       IgM       IgA(m)     IgA(d) 
 
      IgE    Characteristics 
     
  IgD 
        
 
Structure 
 
Monomer 
 
 
 
Pentamer 
 
 
 
Monomer 
 
 
Dimer  
(with secretory 
component)
 
  
Monomer 
 
    
Monomer 
 
   
 
Percentage of 
total serum 
Antibody 
    
  80% 
   
5-10 % 
Represent 
80% of total 
IgA 
   Represent   
  15% of total 
IgA 
    
  0.20% 
 
0.05% 
 
Location 
  Blood,  
  Lymph,  
   intestine 
 Blood, 
Lymph 
Blood, 
Lymph, 
  Secretions    Blood,   
   Lymph 
Bound to 
mast and 
basophil 
cells 
throughout 
body, blood 
 
(tears, saliva, 
mucus, milk, 
gastrointestinal, 
respiratory and 
genitourinary 
tracts) 
 
Half-Life in 
Serum 
23 days 5 days 6 days 6 days 3 days 2 days 
 
Complement-
Fixation 
 
Yes 
 
Yes 
 
No 
 
No 
 
No 
 
No 
 
Placental 
Transfer 
Yes No No No No No 
 
Known 
Functions 
Enhance 
Phagocyto
sis, 
neutralize
s toxins 
and 
viruses, 
protect 
foetus and 
new born 
Effective 
against 
microorganis
ms and 
agglutinating 
antigens, first 
antibodies 
produce in 
response to 
initial 
infection 
Shows a good 
response 
to proteins 
antigen and to 
lesser degree 
to 
lipopolysacch-
arides. 
Localized 
protection on 
mucosal 
surface 
Presence 
on B-cells 
functions 
in 
initiation 
of 
immune 
response, 
upper 
digestive 
tract 
Allergic 
reaction, 
possibly 
damage to 
parasitic 
worms 
1.2.2.10. Function of antibodies 
The function of an antibody results in antigen neutralisation/destruction, and this 
can occur by various methods including agglutination, opsonization, antibody 
dependent cell mediated cytotoxicity (ADCC), complement mediated lysis and 
inflammation, and neutralization [12, 67]. 
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1.2.2.10.1. Agglutination 
This occurs when antibodies interact with particulate antigens and cause a clumping 
of particles. Smaller clumps are eliminated by phagocytosis, but large clumps may 
result in damage to tissues. IgM and IgG can work as agglutinins, but IgM is more 
efficient due to its pentameric structure [12, 67].  
1.2.2.10.2. Opsonization                                                                                                         
During opsonization, higher concentrations of IgG antibodies (opsonic antibody) 
are attached to larger antigens, and they bind with their Fc regions to several Fc 
receptors on the surface of macrophages and neutrophils. This binding induces a 
signal-transduction pathway that leads to the phagocytosis of antigen-antibody 
complex. The pathogen is then killed by various mechanisms, such as enzymatic 
digestion, oxidative damage and membrane disruption by antibacterial peptides [12, 
67].  
1.2.2.10.3. Antibody-dependent cellular cytotoxicity (ADCC) 
Macrophages, neutrophils, eosinophils and NK cells have cytotoxic mechanism that 
destroy tumour cells and viral infected cells; their Fc receptors interact with IgG 
antibodies bound to the target cells and secrete specific components, such as lytic 
enzyme, perforin and TNF, which help to kill the target cell [12, 67]. 
1.2.2.10.4. Complement mediated lysis and inflammation 
The formation of an antigen-antibody bond can activate blood complement proteins 
to bind to the antibody CH2 domain of the Fc region, and this cascade of 
complement proteins results in membrane attack complex formation on the cell wall 
of pathogens, which produces a functional pore. Thus, the water and electrons of 
pathogenic cell are lost and this disturbs the osmotic stability of the cell. The 
complement cascade can also lead to phagocytosis by macrophages and 
neutrophils, and opsonisation, which can induce an inflammatory response [12, 67].  
1.2.2.10.5. Neutralization 
Studies have shown that antibodies can neutralize soluble toxins, which are secreted 
from viruses, bacteria or fungi and prevent them from damaging cells [12, 67].  
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1.3. Cigarette smoke and the immune system 
Cigarette smoke (CS) has numerous toxic chemical constituents, which can be 
characterized as having cytotoxic, mutagenic, carcinogenic, and antigenic 
properties (Figure 1.11) [68, 69]. These toxic ingredients of CS quickly dissolve in 
the fluids of oral and airway epithelial linings, and are systemically taken up in 
either passive or active inhalation. They enter the body mainly through the 
pulmonary alveoli and are spread into all tissues by the blood. The immune 
protectors in the blood, such as B cells and T cells, can react to these stimuli. 
Chronic inhalation of CS has adverse effects on both the innate and adaptive 
immune systems, which consequently leads to an immunological impairment [4, 
70].  
In the 1960s, the effects of tobacco-smoke on immune and inflammatory processes 
were recognized for the first time. Studies of the mechanism of how CS impacts on 
the immune system have found that there are numerous toxic effects, such as 
carcinogenesis which occurs directly or indirectly with genetic or epigenetic effects 
and altered gene functions (DNA repair, and tumour suppressor genes), and CS can 
trigger multiple mechanisms to produce cancer and other diseases [4].  
Molecular studies have shown that, in the presence of smoking components, several 
nicotinic receptors are up-regulated in B cells [71], and long-term exposure to 
nicotine can suppress B cells secretions, block the cell proliferation and 
development, and completely destroy the standard immune functions [72-75]. 
Therefore, all these results show that smoking causes abnormal changes in the 
immune system and produces diseases partly through the dysregulation and 
impairment of B cells [75-79]. Several studies have determined that smoking can 
enhance the incidence of COPD and emphysema [75, 80-82], asthma [83], chronic 
periodontitis [75, 84, 85], and inflammatory reactions, which highlights the 
importance of the effect of smoking on diseases [75, 86].  
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Figure 1.11: CS is a combination of thousands of chemical compounds, 
produced from the burning of tobacco.  
These compounds are classified according to their known effects: 1) numerous 
carcinogenic toxins, 2) addictive CS toxins; although many chemicals contribute 
directly or indirectly to the addictive nature of CS, nicotine is the major one. 3) 
immunomodulatory factors such as nicotine, carbon monoxide, ROS, and acrolein 
[4].  
1.3.1. Mechanisms of how cigarette smoke extracts exert 
inflammatory and suppressive effects on immune cells  
Studies have shown that burning of tobacco is one of the important sources of many 
reactive oxidative substances (ROS) that do not exist in the raw tobacco leaf and 
are not trapped by cigarette butt filters [87]. The products of tobacco burning can 
be divided into gaseous and particulate constituents [68, 88]. ROS in the gaseous 
phase is short lived and mainly impacts the upper airways; whereas the particulate 
phase has highest concentration of toxic CS components and can generate more free 
radicals. In the mucosal surfaces lining the oral cavity, sinuses, and airways, these 
gaseous and particulate CS components start to react with the immune system [4, 
87]. These ROS cause many harmful effects on epithelial cells lining the airways 
through stimulation of the peroxidation of lipids and other cell membrane parts, 
activation of oxidative-sensitive cellular pathways, and they can cause destruction 
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of DNA [4, 89]. ROS can also trigger epithelial cell intracellular signalling 
cascades, generating IL-8 and TNFα and resulting in stimulation of inflammatory 
genes [4, 90, 91]. The secretion of these inflammatory mediators leads to 
stimulation of chronic immune cell recruitment and inflammation.  
CS can stimulate T-cells to proliferate and produce cytokines that mediate 
important biological functions; CS enables the generation of Th2 which stimulates 
the production of IL-4, and suppresses Th1 cells [4, 92-96]. Studies have found that 
there is inhibition of the activation of dendritic cells after severe exposure to 
cigarette smoke extract (CSE), which leads to decreased production of IL-12 (Th1 
polarizing) and IL-23 (Th17 polarizing) cytokines [4, 93, 97]. Similar results have 
been observed in other studies which found, lower concentrations of IL-12 and IL-
23 were secreted from lung and systemic dendritic cells isolated from mice who 
were exposed to CS [97]. These studies also found lung eosinophils numbers were 
higher in mice exposed to CS, which is a marker for Th2 inflammation, and 
decreased Th1 cytokines levels [4, 98]. Studies in animal models have shown CS 
increased Th2 polarized eosinophilic airway inflammation [96], which was similar 
to the results of in vitro stimulation of peripheral blood T-cells of individual 
smokers, as they formed higher concentrations of IL-13 (Th2 cytokine) compared 
to the non-smoker control group [4, 95]. Whether CS stimulates Th17 inflammation 
is not fully understood, although some studies suggesting that chronic CS exposure 
could stimulate Th17-mediated immunity [99] and increased the occurrence of 
inflammatory diseases that accompany Th17 inflammation [4, 100, 101]. The 
mechanisms by which CS activates Th2 and Th17 inflammation are yet to be fully 
elucidated, but they may include inhibition of Th1 polarization and affecting 
cytokine production [93], altered activation of antigen-presenting cells [96, 97], 
stimulation of Th2 polarization, effecting genetic factors, and probably causing 
direct effects on T-cells. The differences between the observations in these studies 
could be due to variations in the techniques used to extract CS, differences in the 
models of exposure, and additional co-factors [4, 94, 102]. 
1.3.2. Mechanism of how CS alters mucosal immunity  
The airway epithelium protects the body from many invaders through the control 
of the immune system response. CS can immediately stimulate the airway 
epithelium, and this results in an immediate influence on chemokine and 
Chapter 1                                                                                   General Introduction 
33 
 
inflammatory mediator secretion (Figure 1.12) [103-105]. This reaction is due to 
epithelial cells expressing TLRs which identify pathogen-associated molecules 
[105]. For instance, TLR3, which is expressed on airway epithelial cells, can 
combine with viral RNA to cause an excessive amount of chemokines to be secreted 
[4, 106]. Also, current or prior smokers, and acute pneumonia patients, have 
significantly decreased levels of beta-defensin-2 in their pharyngeal fluid and 
sputum [4, 107]. Studies have also shown that CS can greatly reduce mucosal ciliary 
motility and raise goblet cell numbers, which have a role in protecting mucous 
membranes, and it can also induce mucus hyper-secretion [4, 90]. These changes 
could possibly cause persistent stimulation of mucosal epithelium with reduced 
anti-microbial action in relation to the clearance of infection, and this could help to 
clarify the increased probability of smokers undergoing microbial colonization and 
infection. 
The components of CS can trigger numerous cell-signalling pathways, affecting 
cell stimulation and regulation of inflammation, the cell cycle, and other regulatory 
genes. For example, studies have reported that CS can affect mitogen-activated 
protein kinases (MAPK), nuclear factor kappa-B (NF-κB), signal transducer and 
activator of transcription (STAT), and activatory protein-1 (AP-1). NF-κB plays a 
crucial role in controlling the immune response to infection, and improper control 
of NF-κB can result in cancer and inflammation; STATs are a family of intracellular 
transcription factors that mediate various roles in cellular immunity, proliferation, 
and apoptosis, and AP-1 controls gene expression in response to various stimuli, 
such as cytokines, bacterial and viral infections [4, 97, 102, 108, 109]. Due to the 
effects of CS on NF-κB and AP-1 transcription factors, it can lead to changes in 
chemokine production, corticosteroid resistance, responsiveness to acute 
pathogens, and altered cell death regulation [4, 109-112]. 
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Figure 1.12: CS regulates inflammation and stimulates chronic inflammation 
in the airways by various mechanisms.  
Directly by triggering epithelial and immune cells to stimulate the secretion of pro-
inflammatory factors and promote the upregulation of other immune cells such as 
neutrophils, macrophages, T-cells, and dendritic cells. CS can also damage the 
innate host defence mechanisms, reduce the innate response to pathogens, and 
change the adaptive immune response to inhaled antigen, which leads to chronic 
injury and inflammation of the airways. Recurring injury combined with abnormal 
responses to self-antigens and co-existent pathogen colonization might increase the 
progress of autoimmunity, which further extends tissue damage and inflammation 
(This figure has been adopted from reference number [4]).  
1.3.3. Cigarette smoke and innate immunity 
The lungs are an important route for environmental pathogens and antigens to enter 
the body; in the respiratory tract, the mucociliary escalator of the large airways 
eliminates most of the inhaled external substances, and alveolar macrophages 
(AMs) and other monocytes play an important role in innate immunity in the lungs. 
CS is a significant risk factor for acute respiratory tract disease and COPD; studies 
have shown that CS increases the AM numbers by several fold, leading to increased 
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concentrations of lysosomal enzymes and secreted elastase, which may cause 
damage to connective tissue and parenchymal cells of the lung, contributing to 
COPD pathogenesis [113]. Moreover, AMs from smokers release significantly 
higher levels of reactive oxygen radicals and have higher myeloperoxidase activity, 
which are considered to be crucial mediators in the killing of intracellular 
pathogens, but in spite of this increased activity, AMs from smokers have a reduced 
ability to phagocytose and kill bacteria [5, 114]. In addition, several studies have 
established that smokers’ AMs have impaired function and secrete lower amounts 
of cytokines, which are important in the regulation of the early immune response 
of the host to pathogens [115]. Experiments in animal models have shown that 
smoking causes various morphological, biochemical and enzymatic alterations in 
AMs that can damage the anti-bacterial defence and the inflammatory response in 
the lungs [116]. 
Comparisons between healthy non-smokers, ex-smokers with COPD, and current 
smokers show that the current smokers with or without COPD have the highest 
proportion of activated CD8+ T lymphocytes, NKT cells and NK cells in their 
peripheral blood. Therefore, these results suggest that smoking affects the 
activation of the systemic killer cells. Furthermore, there is a positive correlation 
between CD8+ T-lymphocyte and NK cell activation with the number of cigarettes 
that are currently smoked. However, there is no correlation between cell activation 
and lung function, so cell activation is more related to smoking habits than to 
disease progression. Overall these studies have suggested that systematic activation 
is related to smoking per se, while lung activation is related to COPD progression, 
and the activation of killer cells in COPD airways can play a role in COPD 
pathogenesis [117]. Similar studies have indicated that, in BALF, the numbers of 
CD8+CD25+ T-lymphocytes are significantly lower in ex-smokers compared with 
current smokers with COPD [118]. 
1.3.4. CS and adaptive immunity 
CS increases the number of human blood leukocytes, but they have lower functional 
activity. Several investigations have shown that long-term smoking drastically 
decreases serum Ig levels in humans, and animal studies have shown that a 
consequence of exposure to CS is a significant reduction in the antibody response 
to variety of antigens, as well as increased autoantibody levels. This could explain 
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the higher susceptibility of smokers to certain autoimmune diseases, for example, 
rheumatoid arthritis [119]. Moreover, investigators have observed that T cells from 
smokers have a reduced ability to proliferate and show lower functional activity, 
suggesting a weakened immune response [5, 70]. Studies in Caucasians showed 
that smoking increased the numbers of peripheral-blood CD4+ cells, whereas 
smoking caused a decrease in T-cell numbers in African-Americans [120]. In 
COPD patients, the numbers of NK and NKT cells are increased in induced sputum 
but decreased in peripheral blood, while CD8+ T-lymphocytes are increased in both 
the peripheral airways and lower respiratory tract [121, 122]. In addition, 
experiments in animals have shown that CS that contains higher concentrations of 
nicotine and tar stimulate alterations in T-cell response more than smoke that 
contains lower levels of these components, suggesting these components play a key 
role in the observed changes after smoking [5, 70]. 
1.3.5. Effects of CS on Immunoglobulins 
There are several studies that confirm that serum IgG, IgM and IgA levels are lower 
in smokers than in non-smokers by 10-20 % [123-125]. In terms of IgA, Barton et 
al. (1990) reported that, in healthy individuals, salivary IgA levels were lower in 
smokers than in non-smokers, whereas salivary IgM levels were higher in smokers, 
and the effects on IgA were reversed after stopping smoking. Similarly, smokers 
with head and neck tumours had lower salivary IgA and higher salivary IgM 
concentrations compared with non-smoking subjects. Overall this research provides 
evidence that there is an effect of smoking on mucosal immunity, which was 
confirmed by studies that, in a previous examination of salivary IgA in mixed 
unstimulated saliva, showed that tobacco smokers had decreased levels of salivary 
IgA when compared with the normal group [126, 127]. Decrease of secretory IgA 
in saliva could be caused by an impact on the salivary glands responsible for the 
formation of the secretory IgA or on the cells of the immunological system involved 
in the production of the IgA molecules [127, 128]. Conversely, Norhagen et al. 
(1998) reported that, in unstimulated saliva, immunocompetent smokers have 
higher levels of salivary IgA that may help in protection of oral mucosa, they 
showed there to be lower levels of IgG and IgM in stimulated saliva (i.e. induced 
by chewing paraffin wax) and they surmised that this may decrease inflammation 
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in oral mucosa [129]. Other research showed that serum IgA levels are higher in 
healthy smoking individuals compared with COPD smoking patients [130]. 
There is some conflicting evidence, however, that shows that there were no 
significant differences in salivary IgA, IgG, while IgM was significantly lower in 
smoking compared to non-smoking individuals [131], and Lie et al. (2002) report 
similar levels of salivary IgA between gingivitis trial smokers and non-smokers 
[132], which is supported by other studies that found no evidence of a significant 
difference in serum IgA levels between smoking and non-smoking individuals 
[133, 134]. Further contradictory evidence comes from studies using broncho-
alveolar lavage fluid (BALF), some found reduced IgA levels in smoking 
individuals [135], whereas other studies found enhanced levels of IgA in the BALF, 
which may be due to differences in experimental set up, but overall these results 
suggests further study is required [136, 137]. 
In terms of IgM levels, some studies have shown that there are no significant 
differences in the levels in serum between smokers and non-smokers [138], but in 
saliva researchers have found significant increases in salivary IgM levels compared 
with non-smokers, and this is combined with low levels of salivary IgA  Overall 
there are more studies that indicate that, in stimulated saliva, individuals who have 
IgA immunodeficiency have increased IgM levels, which suggests there may be a 
measurable change [126, 129].    
Studies of IgG indicate that healthy smokers have lower serum IgG levels than non-
smoking individuals [133]. Other research showed that salivary IgG levels are the 
same between smoking and non-smoking individuals [139]; however others  
reported  that salivary IgG levels are lower in smoking compared to non-smoking 
individuals but there is also evidence to suggest that tobacco smoking does not 
affect the compensatory rise in salivary IgG response over IgA deficiency in 
smoking and non-smoking individuals, all of which again suggests more research 
is needed in this area [126] [129, 140].     
Some studies of salivary IgD have shown its levels do not have significant 
differences between smokers and non-smokers, but other research has found that in 
cigarette smokers the level of serum IgD is twice as high as in non-smokers, but 
this returns to normal after smoking ceases. Studies have also indicated that, in 
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COPD patients, the level of IgD in serum and nasal secretions is higher than in 
control individuals, which suggests that the reduced IgD levels may be related to 
progression of COPD [141]. 
Overall there are numerous studies on the consequences of inhalation of smoke on 
the human immune system and the results suggest that the qualitative and 
quantitative effects of CS on the immune system depend on a variety of factors 
including sex, duration of smoking, and ethnicity of the subjects studied. Although 
CS increases the risk of infections in the human body through diminished humoral 
and cell-mediated immunity, the findings vary depending on the conditions used in 
the research studies [5].  
1.4. Protein microarray overview  
Protein microarray is a relatively novel high-throughput technology used to detect 
the amount of an analyte in various samples including serum, saliva, and urine. 
Currently there are many different forms of microarray that are used for different 
purposes: for example, to detect many different substances, to measure gene 
expression at the mRNA or protein level, to discover mutations, for genotyping, to 
(re) sequence DNA, and to find chromosomal changes [142]. 
Protein microarray uses the same concept as the Enzyme-Linked Immuno-Sorbant 
Assay (ELISA) technique; it offers the possibility simultaneously to evaluate a 
variety of analytes across a broad spectrum of concentrations, using smaller 
volumes and at a lower cost than in the traditional method (ELISA). There are many 
different categories of microarrays (platforms), and they all require a high density 
and quantity of biomolecules fixed onto a specific surface. Generally, there are five 
essential steps in microarrays, the attachment of the biomolecules to a platform, 
preparing samples for detection, hybridization, scanning, and analysis of the data. 
Protein-antibody microarray is one of the most common protein microarrays; the 
principle of this array is that the capture antibodies are printed onto a specific slide, 
then the slide is incubated with the samples, followed by the detection antibody; 
this method can be used to detect proteins of interest in biological samples (Figure 
1.13) [143-145].  
Microarray has been used to offer novel insights into the pathogenesis of smoking-
induced disease by examining specific samples, such as the progression of COPD 
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[146-148]. The major advantages of microarrays over ELISAs are microarrays 
require a smaller quantity of sample to run the assay, they have the capacity to 
detect more than one inflammatory mediator in one experiment, they can carry out 
many repeats of the same analyte in the same experimental conditions, and the 
possibility to detect a mixture of proteins across a range of concentrations. All of 
this leads to a reduction in time and cost to run the assay. Although there is evidence 
of the effectiveness of this technology, more effort on the reproducibility, and 
further validation and optimization is necessary before it will be widely accepted in 
medical research [143, 149, 150]. 
1.4.1. Microarray slide surfaces and immobilisation 
The slide surfaces are one of the major sources of variation in development of 
reproducible protein microarrays; the types and chemistry of the slide surfaces 
determine the type of immobilisation between the slide and the protein that is 
printed on it [151, 152]. The printed proteins and the slide surface combine through 
different physical interactions, including Van der Waals, covalent, ionic or 
hydrophobic bonds, that need to be optimised according to the properties of the 
protein of interest, as these interactions should not alter the structure of the protein 
[151, 153]. There are many commercial slides available where the glass of the slide 
is ‘silanized’, which means the slides are covered in a silane solution, each of which 
has a special functional group. Amino-silane, epoxy-silane, hydrogel and aldehyde 
coatings are the most commonly used slide surface modifications, and each offers 
different properties [154]. 
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Figure 1.13: Picture of the BioRobotics MicroGrid II Arrayer. 
1.4.2. Spot size and morphology 
Once the capture antibody or antigens have been printed on the slide surface, they 
can be seen as rounded spots on the slide [155]. The morphology and size of the 
spots depend on the slide surface chemistry and the printing buffer used; some slide 
surfaces can lower spot scattering, causing a reduced spot diameter and improved 
spot morphology [155]. Weak spot morphology can occur from a failure of the slide 
surface to combine with the functional antibodies, which eventually reduces signal 
intensities [156]. The printing buffer can also determine the size and number of 
spots on the surface of slides, which consequently affects the signal intensities of 
the spots. The size of the spots on the existing commercial microarrays have been 
calculated to provide the optimal probe/analyte capture efficiency (50 to 200 μm 
diameter), but any further reduction of the spot size to the nm scale may result in 
reduced efficiency, due to kinetic-limiting behaviour [157]. 
In current research, the silicon pins that have been used could pick up 0.1µl (100nl), 
if they fill completely, assuming they are empty when filled. The way we use them 
is to print a set number of samples (but ensuring the pin does not run out) then refill 
and print again, until all spots of a particular sample are printed, then the pin is 
washed multiple times and is dried before moving to the next sample. 
The numbers of spots produced by a pin full of liquid are dependent on many 
variables: humidity, the type of print solution, the surface, what is in the print 
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solution (protein / DNA /polysaccharides etc), dwell time (i.e. how long the pin 
touches the surface for each transfer, etc).  
On an ideal setup, with a buffer that retains water well (i.e. reducing evaporation), 
with high humidity, using aminosilane or poly-l-lysine slides, the volume of each 
spot is approximately 500pl and, assuming a conservative 50 spots per fill of the 
pin, 20µl of a sample could print 75,000 spots (that would be about 292 x 64 pad 
arrays at  4 replicate spots per sample per array). However, evaporation loss from 
the plate has to be borne in mind, which can be substantial, especially on a slow 
print (i.e. with one pin), and this would lower the estimated number of spots that 
can be printed. Using several pins, and printing one array per slide, avoids much of 
this issue. 
1.4.3. Spot background 
The spot background is an expression used to identify the background signal that 
develops on the spot (or between the spots) in the absence of bound antigen; this 
can decrease the sensitivity of the assay, particularly at the lower end of the 
detection spectrum. The spot background is a result of non-specific binding of 
proteins to the slide which is affected by the slide surface chemistry; it can be 
caused by protein denaturation, which increases the possibility of non-specific 
binding [158]. 
1.4.4. Signal detection and generation 
Fluorescence is one of the most common methods used for signal generation, and 
is produced when a substance absorbs electromagnetic radiation or light of a long 
wavelength (high energy), and then emits light of a shorter wavelength (lower 
energy). The excitation wavelength can be in the wavelengths visible to human 
eyes, or the UV region of the spectrum, and some fluorophores, for example Cy5, 
are excited by wavelengths around 625 nm and emit light in the red spectrum (532 
– 670 nm) [159]. In microarrays, the detection of the signals depends on two 
different strategies, a label-free strategy such as surface Plasmon resonance (SPR), 
or labelled-probes which can be used directly, indirectly or in a sandwich assay 
[160]. The direct method uses labelled antibodies bound directly to the target 
molecule of interest; the benefit of this is that it allows all proteins to be labelled in 
the same way accurately but, conversely, it can cause a high background due to 
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non-specific adsorption of proteins and this may affect the sensitivity of the assay. 
The indirect method works by immobilizing the target antigens first using a primary 
antibody, and then a second labelled antibody is used for detection [161]. 
The most commonly used method in antigen-antibody microarrays in the literature 
is the fluorescence detection method, which includes using Alexa fluor, Oyster or 
fluorescent dyes such as Cyanine [162, 163]. 
An important part of the detection method is the amplification of the signal through 
the addition of biotin, alkaline phosphatase or tyramide signal amplification [164]. 
In this study, a tyramide amplification reagent was used; tyramide signal 
amplification is an enzyme-mediated detection technique that uses the catalytic 
activity of horseradish peroxidase (HRP) to produce high-density labelling of a 
target protein in a sample (Figure 1.14). This process occurs through attachment of 
a probe to the target, then secondary detection of the probe by an HRP-labelled 
antibody or streptavidin conjugate. The amplifier improves the sensitivity of 
immunoassays, including antigen microarrays, and studies have shown that the 
tyramide amplification system considerably improves the performance of antibody 
microarray assays [165].   
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Figure 1.14: Diagram showing tyramide signal amplification (TSA).  
It binds to the antibodies to produce an increased signal. HRP – horse radish 
peroxidase. 
1.4.5. Assay validation  
Assay validation can be described as 'the documentation of the performance 
characteristics of the method in question by specific laboratory investigations to 
ensure it is reliable and suitable for the analytical application'. How well the 
analytical data is accepted depends directly on the criteria used to validate the 
method. The strategy, improvement, establishment, optimisation and revalidation 
of the method should be covered in the validation process. Overall the validation 
process can be defined as a sequence of experiments that investigate the 
performance of an assay including the accuracy, specificity and reproducibility of 
a technique [166-168].  
The first consideration in assay development is the intended purpose of the assay, 
and how to create a series of experiments that could answer the questions that could 
affect the assay [169]. The industrial guidelines for the production and validation 
of an analytical method produced by the U. S. Food and Drug Administration (US 
FDA), and the American Association of Pharmaceutical Scientists (AAPS) can be 
Immobilized Protein 
Tyramide Signal Amplification (TSA)  
HRP react with TSA Reagents 
Primary Antibodies 
HRP-Conjugated  
Secondary Antibodies 
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modified and adjusted depending on the requirements of the analytical method 
being used [170].  
Within the general laboratory, the major manufacturing companies (e.g. BIO-RAD 
and Thermo Fisher), and in house microarray systems, provide protocols for 
different microarray techniques that can be used.  To design valid tests, the 
microarray process can be divided into different stages [171]. First, there is method 
selection: selecting the best manner to measure proteins in biological samples, and 
the best way to run the microarray system; second is development of the microarray 
system, which includes most of the optimisation steps including varying reagents 
and buffers to find the best combination, as this allows validation to take place and 
assesses the performance of the microarray; and finally there is working on the 
accuracy and reproducibility of the assay [172]. Optimisation and validation are a 
joint process whereby improving one parameter has an impact on the other, and 
vice versa. 
For the purpose of this thesis, these three stages can be explained in more detail:  
A) Method selection: in this thesis, the main aim was to build a methodology that 
was highly accurate and precise, and allows for quantifiable detection of multiple 
Igs simultaneously across a variety of biological samples. The microarray technique 
was chosen instead of ELISA as the costs were significantly lower, less sample and 
reagents were needed than a traditional ELISA, and the microarray had the capacity 
to deliver results faster than an ELISA.  Microarray also has a much greater 
dynamic range than ELISA, with 0 to 60,000 fluorescence units compared to 0 to 4 
optical density units. 
B) Method development: The optimal conditions for running the microarray need 
to be optimised for each microarray, this includes assessment of the best printing 
buffer, the best blocking buffer, and the most appropriate slide surface (which was 
assessed by one of the students in our group). All these variables need to be 
inspected in depth and the optimal combination of these factors were then selected 
to move the microarray process forward.  
C) Method performance: running a series of intra and inter variability assays over 
a period of days can test the performance of the assay, and can indicate the accuracy 
and reproducibility of the system. In this investigation the guidelines for the 
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parameters of the assay are based around the FDA Guidance “Bioanalytical Method 
Validation” [173]. 
Once the methodology has been validated against the equivalent ELISA, clinical 
samples can be applied in the microarray assay. 
1.4.5.1. Parameters of assay validation  
Various parameters can be inspected in the validation process for an antibody 
microarray platform. In this study, four parameters have been tested, specificity, 
precision (inter and intra-assay) and limit of detection.  
1.4.5.1.1. Specificity 
Cross reactivity is one of the major issues in an antibody microarray; it is possible 
to determine the activity of other antibodies rather than the one of interest at one 
time, particularly in a mixed antibody arrays. The specificity is the ability to 
measure the presence of an analyte when it is mixed with multiple analytes [174]. 
It is essential that the microarray platform can be specific for single analytes and 
without cross-reactivity with other analytes in the same experiment.  
1.4.5.1.2. Intra assay variation 
Intra assay variation can be defined as the precision acquired when the procedure 
is carried out under the same conditions within a short interval [175]. In the case of 
the microarray this is when the experiment is performed multiple times on the same 
slide, which acts as an indicator of how the precision is within the same day under 
the same conditions. 
1.4.5.1.3. Inter assay variation 
Inter assay variation occurs when the experiment is carried out under the same 
experimental conditions across a few different days. The precision is calculated and 
again acts as an indicator of how the effects vary in slightly different external 
environments (i.e. change in room temperature, light, buffers, reagents). Usually 
the precision is lower than that of the intra assay variation [176]. 
1.4.5.1.4. Limit of detection 
The lower limit of detection (LOD) is the antibody concentration at which an 
analyte can be successfully identified. In terms of the microarray the LOD is 
defined as a point that is above the level of the blank; in this thesis the LOD is 
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calculated as the blank reading plus two times the standard deviation of the blank 
[177, 178]. 
1.5. Aims 
The aim of this study was to optimise and develop a highly-advanced antibody 
microarray technique, applying new reagents that had never been used with this 
technique before. This array was then used to investigate the effects of CS on Ig 
class expression in the oral cavity and systemically through measuring the 
concentrations of different Ig types in saliva and serum specimens in healthy 
smoking and non-smoking subjects, and subsequently in vitro, in the secretions of 
B-cells isolated from buffy coats. 
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2. Optimisation of the ELISA Technique 
2.1. Introduction 
The enzyme-linked immunosorbent assay (ELISA), or enzyme immunoassay 
(EIA), is one of the most common immunological laboratory methods. This assay 
was first established in the 1970s as a substitute for radioimmunoassays, and is 
considered as one of most highly sensitive and rapid methods for measuring the 
concentrations of analytes. ELISAs depend on the separation of specific and non-
specific substances, mainly through sequential binding of antigens and antibodies 
to the solid surface of a polystyrene multi-well plate. The amount of analyte 
correlates with the colour of the end product. Here, an ELISA was calibrated to 
measure immunoglobulin (Ig) isotypes and to facilitate calibration of a more 
advanced technique, namely a protein microarray.  
2.2. Materials and methods 
2.2.1. Materials 
Table 2.1 shows the reagents and materials that were used in the ELISA technique, 
and Table 2.2 describes the types of capture antibodies that were used for our in-
house ELISA. 
2.2.2. Developing the ELISA technique 
2.2.2.1. Choosing a suitable blocking buffer and concentration for 
the different immunoglobulin isotypes to generate standard curves 
Capture antibodies (Table 2.2) were diluted to 1 μg/ml (1:1000) with 
carbonate/bicarbonate buffer (pH = 9.2). Each well of the ELISA plates was coated 
with 100 μl of capture antibody and incubated overnight at room temperature. After 
incubation, the plates were washed 3 times with phosphate buffered saline (PBS) 
containing 0.05 % Tween-20. Wells of the ELISA plates were blocked either with 
I-block in reagent diluent (300 μl/well), 1 % bovine serum albumin (BSA; Sigma) 
in PBS, or with 5 % milk powder (50 mg/ml in PBS). Then, the plates were 
incubated for 1 h at room temperature. 
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Table 2.1: Reagents and materials used for the ELISA technique. 
Materials Sources 
ELISA plates Nunc plates, MaxiSorp 
Carbonate/bicarbonate buffer Sigma-Aldrich 
Phosphate buffered saline (PBS) Sigma-Aldrich 
Tween-20 Sigma-Aldrich 
1 % Bovine serum albumin (Sigma) Sigma-Aldrich 
I-block Tropix, Bedford, MA, US 
Biotinylated anti-human Ig Light chain   κ and λ Sigma/Oxoid 
Human immunoglobulin standards 
Athenas research and 
Technology 
Human IgM, IgG, IgA and IgD ELISA Quantitation sets Cambridge Bioscience 
Streptavidin-HRP Bio-Rad 
Tetra methyl benzidine (TMB) Thermo Scientific 
 
Table 2.2: Concentrations of specific capture antibodies used for all Ig 
isotypes, as well as their sources. 
 
 
Isotype Capture Antibody Concentration Company 
IgG 
Goat anti-human IgG Fc 
(polyclonal) 
1 g/ml 
Sigma-Aldrich, 
Gillingham, UK 
IgA 
Goat anti-human IgA -chain 
(polyclonal) 
1 g/ml 
Sigma-Aldrich, 
Gillingham, UK 
IgD 
Goat anti-human IgD 
(polyclonal) 
1 g/ml Serotec, Poole, UK 
IgM 
Goat anti-human IgM -chain 
(polyclonal) 
1 g/ml 
Sigma-Aldrich, 
Gillingham, UK 
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Following the incubation, the ELISA plates were washed as described above. 
Human immunoglobulin standards (all classes of standard Igs were obtained from 
Athenas Research and Technology Company) were prepared by serial 2-fold 
dilutions across 16 concentrations. I-block was used to dilute the purified Ig 
standards for wells that were blocked with I-block, while BSA was used as a diluent 
for purified Ig standards that were blocked with BSA or milk blocking buffers. 
Standard curves of IgG (100 ng/ml–0.006 ng/ml), IgA (500 ng/ml–0.030 ng/ml), 
IgM (1000 ng/ml–0.061 ng/ml), and IgD (500 ng/ml–0.030 ng/ml) were prepared. 
Next, the diluted standards were applied in triplicate to anti-Ig coated wells and 
incubated for 2 h at room temperature and then washed, as described above. 
Subsequently, detection antibodies (a mixture of 0.5 μg/ml biotinylated anti-human 
Ig light chain κ and 0.5 μg/ml biotinylated anti-human Ig light chain λ antibodies 
were diluted in reagent diluent, added to ELISA plates, and incubated for 90 min at 
room temperature. 
Following the incubation, the plates were washed as described above. 
Subsequently, streptavidin-HRP was diluted 1:200 in reagent diluent and incubated 
in all wells for 20 min at room temperature. After the incubation, the plate was 
washed as described above. Substrate reagent, tetramethyl benzidine (TMB), was 
applied to all wells. The plates were incubated to allow for colour development. 
Stop solution (1.8M sulphuric acid) was then added to stop the reaction after 5–10 
min. Absorbance was measured using a FLUOstar OPTIMA Plate Reader at 450 
nm (Figure 2.1). 
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Figure 2.1: Graphical illustration of the principle of the ELISA technique.  
ELISA plates are coated with capture antibodies overnight. Then, the plates are 
washed and blocking buffer is added. After incubation, the plates are washed again, 
after which standard and/or samples are added, and the plates are incubated for 2 h. 
Subsequently, the plates are washed and biotinylated detection antibodies are 
added. Then, the plates are washed and horseradish peroxidase (HRP)-conjugated 
streptavidin is added to the plates, which are incubated in the dark. After repeat 
washing, a TMB substrate is added and the reaction is stopped by adding 0.18M 
sulphuric acid after colour development. The absorbance is read on a plate reader 
at 450 nm. 
2.2.2.2. Cross-reactivity experiments for studying the specificity of 
the in-house ELISA  
Cross-reactivity experiments were performed to check the specificity of the in-
house ELISA. To investigate the ELISA specificity, a specific capture antibody was 
incubated with a variety of immunoglobulin standards, and then an appropriate, 
species-matched detection antibody was added. These experiments showed whether 
the IgA ELISA detects only IgA (not IgG or IgM); whether the IgG ELISA detects 
Capture AB Blocking buffer 
Standard 
Detection AB 
Streptavidin 
HRP 
Substrate 
solution 
 
Stop solution Read on plate reader at 450 nm 
Chapter 2                                                       Optimisation of the ELISA Technique 
51 
 
only IgG (not IgA or IgM); and whether the IgM ELISA detects only IgM (not IgA 
or IgG).   
2.2.2.2.1. Cross-reactivity experiments for determining IgG 
specificity 
Cross-reactivity experiments for in-house ELISAs were repeated 3 times for IgG 
capture to determine their specificity in detecting the appropriate class of antibody. 
In the cross-reactivity experiments, the same ELISA steps described above were 
followed by adding an anti-human IgG Fc-specific antibody as the capture 
antibody, after which serially diluted IgM, IgG, and IgA immunoglobulin standards 
were detected with a mixture of 0.5 μg/ml biotinylated anti-human Ig light chain κ 
and 0.5 μg/ml biotinylated anti-human Ig light chain λ antibodies.  
2.2.2.2.2. Cross-reactivity experiments for determining IgM 
specificity 
In this experiment, the same steps described above were followed using an anti-
human IgM -chain-specific antibody (1 μg/ml; Sigma-Aldrich, Gillingham, UK) 
as the capture antibody, after which serially diluted IgM, IgG, and IgA 
immunoglobulin standards were detected with a mixture of 0.5 μg/ml biotinylated 
anti-human Ig Light chain κ and 0.5 μg/ml biotinylated anti-human Ig Light chain 
λ antibodies. 
2.2.2.2.3. Cross-reactivity experiments for studying the specificity 
of the ELISA quantitation set for detecting IgM, IgG, IgA, and IgD 
Human IgM, IgG, IgA, and IgD ELISA quantitation sets were obtained from 
Cambridge Bioscience, and cross-reactivity experiments were performed to 
determine their specificity in measuring only the appropriate antibody. Increasing 
concentrations of capture and detection antibodies were tested to determine the 
optimum concentrations for further experiments.  
2.3. Results 
2.3.1. Choosing a suitable blocking buffer and concentration for 
detecting different Ig isotypes to generate standard curves 
The in-house ELISA was developed by testing different blocking buffers to 
optimise the specificity of Ig detection. BSA was found to be the best blocking 
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buffer for specific detection of the different Ig isotypes, as it gave the best end-
product optical density values and a low background, and it generated a linear 
standard curve. Moreover, a carbonate-bicarbonate buffer was effective as a coating 
buffer for detecting all Ig isotypes because it generated a more alkaline medium 
than did PBS, which enhances the binding of anti-human Ig to ELISA plates. Each 
Ig was investigated with different concentrations to generate standard curves 
(Figure 2.2). 
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Figure 2.2: In-house developed ELISA, comparison of the results obtained 
using three different blocking buffers.  
a) Mean (n =3) obtained for the IgG standard curve. b) Mean (n =3) obtained for 
the IgM standard curve. c) Mean (n =3) obtained for the IgA standard curve. d) 
Mean (n =3) obtained for the IgD standard curve. For each Ig type the average 
absorbance for the 3 different blocking buffers (3 % BSA blocking buffer, the I-
Block Protein-Based Blocking Reagent, and 5 % milk powder) are shown. The I-
Block reagent showed a high background and a lack of dynamic range in the 
standard curves, therefore BSA was chosen as a suitable blocking buffer for future 
experiments. 
2.3.2. ELISA cross-reactivity results 
2.3.2.1. Results of studying the specificity of the in-house ELISA 
with Igs 
Cross-reactivity experiments showed that the IgG-capture antibodies detected both 
IgM and IgA (Figure 2.3a). In addition, the IgM-capture antibodies detected both 
IgG and IgA (Figure 2.3b). Based on these results, the Ig-capture antibodies were 
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not specific enough to yield accurate results. Thus, the Cambridge Bioscience 
Quantitation Set reagents were used in subsequent experiments.  
 
Figure 2.3: Cross-reactivity experiments for the in-house ELISA.  
(a) The IgG ELISA showed high cross-reactivity with IgM and IgA, with higher 
values detected for IgM than IgA when the IgG-specific capture antibodies were 
used. (b) The IgM ELISA showed high cross-reactivity with IgG and IgA, with 
higher values for IgA than IgG when the IgM-specific capture antibodies were used, 
but this could also be interpreted as a high background in the case of IgG. 
2.3.2.2. Specificity of the ELISA Quantitation Set in detecting IgM, 
IgG, IgA, and IgD 
Results from cross-reactivity experiments demonstrated the high specificity of the 
ELISA Quantitation Set. As shown in Figure 2.4, the IgG-capture and secondary 
antibodies measured only IgG (not IgM or IgA). Similarly, IgM ELISA detected 
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IgM, but not IgG or IgA; the IgA ELISA detected IgA, but not IgM or IgG; and the 
IgD ELISA only detected IgD, using this set of reagents.  
Due to the many advantages of advanced microarray techniques, the same reagents 
were used to optimize the performance of the microarray-based test. 
 
  
Figure 2.4: Investigation of cross-reactivity between anti-Ig capture and 
detection antibodies of different Ig class specificities with Ig standards of 
different classes.  
(a) IgG standard curves with high specificity; the capture and detection antibodies 
measured only IgG, but not IgM, IgA, or IgD. (b) IgM standard curves with high 
specificity; the capture and detection antibodies measured only IgM, but not IgG, 
IgA, or IgD. (c) IgA standard curves with high specificity; the capture and detection 
antibodies measured only IgA, but not IgG, IgM, or IgD. (d) IgD standard curves 
with high specificity; the capture and detection antibodies measured only IgD, but 
not IgG, IgM, or IgA, The IgD standard was not curve-fitted; thus, the data points 
shown were connected with joining lines. 
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2.4. Discussion 
In the experiments described in this chapter, the “sandwich” ELISA technique was 
optimised and specific Ig isotypes were sandwiched between anti-heavy chain 
antibodies and secondary, labelled anti-light chain antibodies in ELISA plates. 
During coating, a polyclonal anti-human heavy chain Ig isotype (mouse IgG) 
antibody was used as a capture antibody to bind Igs. Carbonate-bicarbonate buffer 
(pH 9.2) was selected as a coating buffer, and it was found that 1 μg/ml of anti-Ig 
antibodies produced detectable levels of Ig isotypes. In addition, the specificity and 
sensitivity of the assays were evaluated. Assay specificity was investigated by 
determining whether the IgA, IgG, and IgM ELISAs detected only the intended Ig 
class, or if cross-reactivity was also observed. When evaluating the assay 
sensitivity, it was important to ensure that the Ig concentrations in samples were 
determined at the linear ranges of the standard curves. The in-house generated 
ELISA showed high cross-reactivity between Igs, which may have been 
compounded by the use of anti-heavy and -light chains secondary antibodies; these 
antibodies can bind to all types of Igs and produce a detectable signal in cases where 
the capture antibody is not pure or specific enough to detect only a single isotype. 
To reach accurate conclusions, experiments were performed with reagents from 
Cambridge Bioscience, which showed sufficiently high specificity and sensitivity 
to assess antibody levels in serum and saliva samples. In these experiments, capture 
and secondary antibodies recognizing the heavy chain of the targeted Ig isotype 
were used to the ensure specificity of the test. 
2.5. Conclusions  
The reagents from Cambridge Bioscience gave high specificity and accuracy in the 
measurement of Ig isotypes, and due to the advantages of the microarray techniques 
in evaluating the levels of analytes, the next chapter focuses on experiments 
designed to select appropriate reagents for this technique, which were subsequently 
used to measure the concentrations of antibodies in samples. 
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3. Optimisation and Validation of Antibody Microarray 
3.1. Introduction 
The antibody microarray technique is used to measure the quantity of proteins that 
are found in biological samples such as serum, sputum, and urine. The principle of 
this technique is based on the use of specific capture antibodies printed onto the 
surface of microarray slides, which can bind their cognate proteins in a sample. 
After the initial interaction of the capture antibody with the target protein, a 
secondary antibody is added to detect the capture antibody-target protein complex. 
In general, microarrays are based on a principle that is similar to that of enzyme-
linked immunosorbent assays (ELISAs), but microarrays often involve reduced 
costs and hands-on time. In addition, microarrays can be used to analyse a single 
slide several times, which enables validation of the results. 
ELISAs are commonly used as a gold-standard technique because they offer high 
sensitivity and specificity; however, a substantial body of research has been 
conducted using microarrays to determine serum antibody concentrations. 
Antibody microarrays are considered to represent an emerging, useful approach for 
detecting disease biomarkers; thus, optimisation and validation studies should be 
performed to facilitate application of this technology in medical research [179, 
180]. 
Three different types of protein microarrays have been developed. Reverse-phase 
protein microarrays offer specificity in detecting modifications of intracellular 
proteins in cell lysates that accompany certain diseases. Functional protein 
microarrays enable the determination of interactions between proteins and other 
significant molecules. Finally, analytical protein microarrays can be used to study 
protein affinities and protein concentrations, as was done in the current research 
[156, 181]. 
During the analytical protein sandwich microarray process, different antibodies 
were printed on microarray slides to serve as capturing antibodies for the analytes 
of interest. Then, the slides were probed with samples, followed by direct detection 
or incubation with secondary analyte-specific biotinylated antibodies, that were 
identified with a fluorescent dye (sandwich microarray) [182]. The principle of 
sandwich antibody microarrays is demonstrated in Figure 3.1. Basically, capture 
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antibodies are printed onto a slide, after which a blocking buffer is added to block 
non-specific binding to the slide. Next, the samples are added, followed by the 
addition of secondary biotinylated antibodies and, finally, a streptavidin-conjugated 
fluorescent dye.  
In general, numerous factors can affect the data generated by an antibody 
microarray, including the types of capture antibody and samples used, the slide 
composition (plastic or glass), and the slide coating (silicon or polylysine), which 
can affect the affinity of each slide for substrates. Selecting an appropriate surface 
chemistry helps generate high-intensity signals after applying unknown samples. In 
addition, protein adsorption and covalent bonding can affect the antibodies that 
attach to the slide surface. These types of slides are recognized as 2-D surfaces, 
whereas slides coated with a polymer matrix are recognized as 3-D surfaces. 
Physical adsorption occurs through hydrogen bonding, ionic bonding, and/or 
hydrophobic interactions, which immobilize the antibodies onto the slide surface. 
Weak, non-covalent interactions can result in partial antibody binding; however, 
this is generally preferable to covalent binding, which can change the protein
structure. Moreover, the choice between direct detection or detection with 
secondary, biotinylated antibodies, as well as the blocking and printing buffers used 
can affect the signal intensity and the background level. 
Different types of printing buffers can be used; thus, it is important to select one 
that does not alter the biological characteristics of the printed proteins. PBS-
trehalose has been used as a printing buffer and contains a naturally occurring sugar 
(trehalose), which has a strong ability to protect proteins from dehydration and 
denaturation, thereby helping to maintain the natural structures of printed proteins 
[183]. Another important buffer that should be considered is the blocking buffer. 
The blocking buffer should be capable of blocking all the other active sites on the 
slide surface to prevent unfavourable binding to other proteins, except for the 
capture antibodies [179]. In this study, glass slides coated with poly-L-lysine were 
printed with highly specific capture antibodies, which led to capture-antibody 
immobilization by adsorption. Furthermore, BSA was used as a blocking buffer 
because it resulted in a low background, compared to other buffers tested.  
In brief, the main advantages of microarrays over ELISAs are as follows; 
microarrays require a lower amount of sample to run the assay, with significantly 
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reduced time and expense. Microarrays also provide the ability to perform multiple 
replicate measurements with the same antibodies during the same experiment, 
under typical experimental conditions. Furthermore, microarrays can be used to 
identify several different proteins over a range of concentrations, in the same 
experiment.  The multiplexing capabilities of microarray also enable 4-6 replicates 
to be performed in a single assay (compared with the 2-3 normally used in ELISA) 
and the post assay analysis procedures then allow poor-performing replicates to be 
excluded based on valid criteria (e.g. spot circularity, uniform pixel density, etc.), 
thereby reducing the coefficient of variation for sample replicates. 
3.2. Materials and methods 
All reagents were warmed to room temperature (20–25 °C) before use. These 
reagents included coating buffer (0.05 M carbonate/bicarbonate buffer, pH 9.6), 
wash solution (0.50 mM Tris, 0.14 M NaCl, 0.05 % Tween 20, pH 8.0), blocking 
solution (50 mM Tris, 0.14 M NaCl, 1 % BSA, pH 8.0), and sample/conjugate 
diluent (50 mM Tris, 0.14 M NaCl, 1 % BSA, 0.05 % Tween-20). Table 3.1 shows 
all materials that were used in the microarray technique.  
3.2.1. Materials 
Table 3.1: List of materials used for the microarray technique. 
Materials Sources 
Biotinylated anti-human IgG (H&L) Biolegend  
BSA  Sigma-Aldrich  
Carbonate/bicarbonate buffer  Sigma-Aldrich  
DMSO (dimethyl sulfoxide) Sigma, UK 
Goat anti-human IgM, Cambridge Bioscience  
Goat anti-human IgA  Cambridge Bioscience  
Goat anti-human IgG  Cambridge Bioscience  
HRP conjugated Goat anti-human IgG-Fc  Cambridge Bioscience 
I- block  Tropix, Bedford, MA, US  
NaCl  Fisher  
PBS-Trehalose  Sigma-Aldrich  
Phosphate buffered saline (PBS) Sigma/Oxoid  
Poly-lysine-slides Sigma-Aldrich 
streptavidin Cy5 fluorochrome  Bio-Rad  
Teramide amplification  Bio-Rad  
Tris-phosphate  Calbiochem  
Tween-20 Sigma-Aldrich  
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3.2.2. Printing slides on the arrayer 
The Human IgM, IgG, IgA, and IgD Quantitation sets from Cambridge Bioscience 
contained all essential reagents required for the experiments discussed in this 
chapter. Each kit included the necessary capture antibody, a standard, and a 
detection antibody. All reagents were reconstituted for the optimisation 
experiments. Initially, the capture antibodies were prepared at a concentration of 
100 µg/ml by dilution in printing buffer (1  PBS containing 50 mM Trehalose; 
Sigma-Aldrich). Then, 20 µl of printing buffer was added to each well of the 
microarray plate, and the capture antibodies were printed on poly-L-lysine slides 
(Catalogue No. 63478-AS; Electron Microscopy Sciences, USA). The plate was 
covered with an aluminium cover and centrifuged for 3 min at 1200  g at room 
temperature. Finally, the plate was placed in the biobank in a MicroGrid II arrayer. 
The slides were placed on a tray in the arrayer, and the required program was run 
to print 16 blocks. For each block, we set the program to print a specific antibody 
5 times in separate rows, and this process was repeated twice in the same block to 
obtain a total of 10 spots for each antibody, but in two separate sets. The printed 
slides were preserved inside a vacuum once the printing was completed.  Further 
details of the printing process and the number of slides that could be printed from 
a given volume of reagent are given in section 1.4.2.  
3.2.3. Amplification                                                                               
One issue seen was low signal intensity with some of the proteins at low 
concentrations. To overcome this problem, an extra amplification step can be 
performed with protein microarrays to increase the signal intensity, as demonstrated 
in previous studies [161, 184, 185]. In the current research, tyramide amplification 
was used for this purpose. Tyramide amplification is based on the use of an HRP-
conjugated detection antibody in the presence of H2O2, which triggers the activation 
and oxidation of biotinylated tyramide, which binds covalently to proteins at 
electron-rich amino acid residues. This results in increasing the amount of biotin 
present at immuno-reactive sites, causing an improvement in the sensitivity and 
signal intensity. In addition, the background level can potentially increase with 
amplification, which may be because the emission wavelength of Cy5 changes from 
450 nm (without tyramide amplification) to 380–400 nm (with amplification). 
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3.2.4. Slide preparation 
Capture antibody (goat anti-human IgG-Fc) was diluted to 100 g/ml in 2 different 
printing buffers (carbonate/bicarbonate buffer and PBS-trehalose) to compare 
them. Two wells of the microarray plate were coated with 20 l capture antibody, 
and the plate was covered with an aluminium cover and centrifuged at 1,200 x g. 
Then, the plate and polylysine slides were placed in a block in the arrayer, and a 
programme was run to print 16 blocks in each slide. Slides were held under a 
vacuum overnight. On the next day, the slides were blocked with I-block in reagent 
diluent (100 l/block) or BSA blocking buffer to compare these blocking buffers. 
Then, the slides were shaken for 1 h at room temperature. After incubation, the 
slides were washed 3 times with PBS containing 0.05 % Tween-20 on the shaker 
for 3 min each wash. During incubation, human IgG standard was prepared at a 
concentration of 500 ng/ml and serially diluted with reagent diluent with 2-fold 
dilutions across 8 points. The resulting concentrations in the dilution series were 
1000, 500, 250, 125, 62.5, 31.25, and 15.6 ng/ml. One block was used as a negative 
control, into which only the reagent diluent was added. 
Following incubation, the slides were washed as described above. Then, 100 l of 
the HRP-conjugated detection antibodies were added and the slides were incubated 
for 1 h at room temperature on a shaker. 
Following incubation, the plates were washed, as described above. Subsequently, 
100 l tyramide amplification reagent was prepared (4:1:4) applied to the slides, 
and incubated for 10 min at room temperature. After the incubation, the slides were 
washed as described above, and 100 l Cy5-conjugated streptavidin (1:1,000 in 3 
% BSA) was applied to each block. The slides were incubated for 15 min on the 
shaker in the dark. Finally, the slides were released from the holder, washed in ultra-
pure water for 5 min, and centrifuged for 3 min. Fluorescence was detected using a 
GenePix scanner 4200AL at a wavelength of 635 nm (Figure 3.1). 
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Figure 3.1: Principle of the sandwich antibody microarray.  
Initially, a specific capture antibody is printed on poly-L-lysine-coated slides. 
Subsequently, serum or saliva samples or Ig standard are applied to the slide and 
attach to the immobilized capture antibodies on the slide. After a 1-h incubation 
period, an HRP-conjugated secondary antibody is added, then biotinylated-
tyramide amplification reagent was added and Cy5-conjugated streptavidin was 
used to detect bound antibodies by scanning the slides in a laser-based scanner. The 
signal intensities produced at each spot were proportional to the antibody 
concentration in the sample. 
3.2.5 Scanning of slides 
After processing, slides were immediately scanned with a GenePix 4200AL 
microarray scanner, to measure the fluorescent dye (Cy5 Fluor 635). The GenePix 
scanner has a dynamic detection of signal above background noise in a range of 0 - 
65,535; therefore, setting the laser power was a crucial step to obtain the lowest 
background noise and highest signal intensities. After investigation, these 
adjustments were made to prevent photo bleaching: 80-90 % laser power, (photo-
multiplier tube voltage set to PMT 370-400, 10 μm pixel size, 20 μm focus position, 
and a scanning wavelength of 635 nm (laser standard red). Slides were inserted in 
to the slide carrier, loaded into the scanner, scanned, and images produced were 
saved in the manufacturer’s recommended format (multiple-image TIFF). 
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3.2.6 Slide analysis 
After scanning the slides, a GenePix Array List (GAL) file was analysed using 
Axon GenePix Pro 6 Microarray Image Analysis software (version 6, USA) to 
detect the spots that were scanned. This file was first created in Excel, using the 
same order of the capture antibodies in the plate, as follows: 
Plate Row Column Name Dilution 
1 A 1 IgG capture antibody 1 
1 B 1 IgM capture antibody 1 
1 C 1 IgA capture antibody 1 
1 D 1 IgD capture antibody 1 
Then, a file was saved as a comma-defined file (csv), which was then converted to 
a GAL file by following the steps in the Clone Tracking Wizard in the computer of 
the arrayer. In GenePix Pro, when ready for the analysis, the GAL file was 
associated with the spots to be classified. The signal intensities of the scanned spots 
were converted in GenePix Pro 6 to numerical values and gpr files were generated 
containing multi-parametric data, including the raw data for each arrayed protein, 
localization, identification variables, signal intensity and background noise. The 
median fluorescence of each spot was measured and the background values were 
subtracted. The GenePix software read spots according to their morphologies, 
allowing all spots with irregular shapes or low signals to be filtered (i.e. spot 
circularity < 65) and excluded using Microsoft Excel 2010; the data were further 
processed using GraphPad Prism 6.0 software (GraphPad Software, USA) (Figure 
3.2, Figure 3.3). 
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Figure 3.2: Diagram of the microarray assay protocol for quantification of 
total Ig antibodies.  
(a) printing: a printed slide of 64-pads, containing printing replicates across each 
pad, (b) capture anti-human Igs antibodies used to bind total Igs in serum/saliva, 
subsequently detected with secondary antibodies, (c) fluorescent image of a pad, 
and (d) data analysis of the scanned images. 
 
 
Figure 3.3: Schematic diagram shows the steps for generating the numerical 
numbers and curves.  
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3.3. Developing the antibody microarray 
The purpose of these experiments was to develop suitable Ig standard curves that 
could be used to measure Igs in serum and saliva samples. 
3.3.1. Generating an IgG standard curve 
3.3.1.1 Determining the best printing buffer  
The capture antibody (goat anti-human IgG-Fc) was diluted to 100 g/ml in 2 
different printing buffers (carbonate/bicarbonate buffer and PBS-trehalose) to 
compare them. Two wells of the microarray plate were coated with 20 L. Then, 
the assay was completed, following the steps described above. HRP-conjugated 
goat anti-human IgG-Fc was used as secondary antibody and biotinylated tyramide 
amplification reagent was applied, followed by streptavidin-Cy5 and DMSO was 
used to fix the spots. 
3.3.1.2 Determining the optimal blocking buffer 
In this experiment, slides were coated with capture antibody (goat anti-human IgG-
Fc) in trehalose printing buffer containing either I-block or BSA (BSA with NaCl 
and Tris-phosphate) in each of 8 blocks. The highest concentration of IgG was 125 
ng/ml, which was serially diluted with reagent diluent (2-fold dilutions) across 8 
points. Secondary HRP-conjugated goat anti-human IgG-Fc antibody was applied, 
followed by biotinylated tyramide amplification reagent and then streptavidin-
conjugated Cy5. 
3.3.1.3 Using a biotinylated secondary antibody 
To improve the signal intensity, the secondary antibody was changed from a non- 
biotinylated to a biotinylated detection antibody. In this experiment, 2 dilution 
series were prepared; in the first series, the standards ranged from 125 ng/ml to 1.95 
ng/ml, while the second dilution series started at a concentration of 1.95 ng/ml. 
Biotinylated anti-human IgG (H & L) was used as a detection antibody, instead of 
the HRP-conjugated goat anti-human IgG-Fc, and therefore the tyramide 
amplification reagent was not applied. In addition, the capture antibody was applied 
at 50 and 100 µg/ml to determine if there was any difference between these 
concentrations. However, this secondary antibody showed a lack of specificity, and 
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it was therefore decided it would be better to use the HRP-conjugated, goat anti-
human, IgG-Fc with amplification instead. 
3.3.1.4 Using an amplification reagent and an HRP-conjugated 
goat anti-human IgG-Fc as a secondary antibody at different 
concentrations 
In this experiment, 5 different concentrations of the non-biotinylated, HRP-
conjugated, goat anti-human IgG-Fc secondary antibody were prepared for use in 
IgG standard curves (1:100,000, 1:200,000, 1: 400,000, 1:800,000 and 
1:1,600,000). The human IgG standard was prepared at a high concentration of 500 
ng/ml, which was serially diluted with reagent diluent by 2-fold increments across 
8 points. 
3.3.2. Generating IgM and IgA standard curves 
The previous procedure was applied to perform the assay. Capture antibody (goat 
anti-human IgM, goat anti-human IgA, and goat anti-human IgG) were diluted to 
100 g/ml in PBS-trehalose buffer. Subsequently, 2 wells of the microarray plate 
were coated with 20 l of these capture antibodies. The human IgM and IgA 
standards were prepared at the top concentration 500 ng/ml, then diluted with 
reagent diluent by 2-fold steps across 8 points. Three secondary anti-body 
concentrations of HRP conjugated Goat anti-human IgM and Goat anti-human IgA 
were prepared (1:400,000; 1:800,000 and 1:1,600,000).  
3.4. Antibody microarray validation test 
3.4.1. Cross-reactivity test 
Cross-reactivity assessment is an important validation parameter in protein binding-
based assays, and in the case of this study, antibody microarray platforms. To 
determine if cross-reactivity occurred in this microarray platform, the following 
experiments were conducted: first, to examine the specificity of detecting standard 
isotypes, a microarray panel was printed with specific capture antibodies, different 
protein standards were added, and then a particular detection antibody was used. 
Secondly, to examine the specificity of the capture antibody, a microarray panel 
was printed with different capture antibodies, after which various standards were 
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added, followed by the addition of detection antibodies and downstream processing 
(Figure 3.4). 
3.4.1.1. Examination of the cross-reactivity for IgG with IgM and 
IgA by using biotinylated anti-IgG (H & L) as detection antibody 
Based on the previous result, which gave rise to a good standard curve with 
biotinylated anti-human IgG (H & L), the cross-reactivity was checked.  
3.4.1.2. Examination of IgG cross-reactivity with IgM and IgA 
using an HRP-conjugated, goat anti-human IgG-Fc as the detection 
antibody 
Based on the previous result, the cross-reactivity was checked to determine the 
specificity of the reagents. HRP conjugated Goat anti-human IgG-Fc (1:800,000) 
was used as a secondary antibody. 
 
Figure 3.4: Determining the specificity of capture and detection antibodies.  
a) A mixture of Ig standards was applied to the same pad; only one class of Ig was 
able to bind to the capture and detection antibodies (exemplified here detection of 
IgG). b) Different capture antibodies were printed on different pads (exemplified 
here with anti-IgG or anti-IgA), but only the specific one has the ability to bind to 
the corresponding Ig standard (exemplified here with IgG). 
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3.4.1.3. Examination of the cross-reactivity for IgM with IgG and 
IgA, also IgA with IgG and IgM 
Four different wells of the microarray plate were coated in order, with 20l of 
capture antibody (Goat anti-human IgG-Fc, IgM-Fc, IgA-Fc, and IgD-Fc), which 
was diluted to 100 g/ml in a PBS-Trehalose printing buffer. Human IgG, IgM, 
IgA and IgD standards were prepared at the top concentration 125, 500, 500, and 
500 ng/ml, respectively, and diluted with a reagent diluent by 2-fold steps across 8 
points. Then the same procedure was applied to complete the assay. HRP 
conjugated goat anti-human IgM (1:800,000) and IgA (1:1,600,000) were prepared 
and applied to the slide. 
3.4.2. Precision tests 
3.4.2.1. Intra- and inter-assay variability 
Intra-assays and inter-assays were performed to establish the precision of the 
microarray assay. In the case of intra-assays, the experiments were repeated on the 
same slide on the same day while, in inter-assays, experiments were performed on 
three different days. Up to 6 serum samples from healthy donors were collected and 
diluted for measuring immunoglobulins. Then, the mean and standard deviation of 
the replicates were calculated to estimate the precision of the microarray assay. 
3.5. Results 
3.5.1. Developing the antibody-microarray 
3.5.1.1. Determining the best printing buffer and blocking buffer 
Previous studies in our group showed that PBS-trehalose printing buffer yielded 
better spot shapes than did the carbonate/bicarbonate buffer [231], making it 
suitable for printing slides in the arrayer. BSA showed less background than did I-
block, so BSA was selected as a blocking buffer for the microarray studies (Figure 
3.5). 
3.5.1.2. Determining the best capture-antibody concentration for 
printing onto slides and using a biotinylated secondary antibody 
To determine the effect of the capture antibody concentration, a comparison 
between two capture-antibody concentrations (50 and 100 ng/ml) was conducted 
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(Figure 3.6). The results showed that 100 ng capture antibody/ml generated better 
standard curves than the 50 ng/ml did. In addition, the results showed a good 
standard curve was produced when the higher concentration of 125 ng/ml was used, 
while the dilution series that was generated with 1.95 ng/ml as the highest 
concentration did not generate any spots (Figure 3.7). However, the biotinylated 
secondary antibody showed poor specificity (section 3.5.2.1.1); therefore, the 
secondary antibody was changed to the HRP-conjugated goat anti-human IgG-Fc. 
 
 
Figure 3.5: Determining blocking buffer suitability.  
Poly-L-lysine slides were printed and processed with two different blocking buffers 
(BSA and I-Block), BSA (b) improved the level of signal intensity in terms of the 
shapes of the spots, compared to I-Block (a).  
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Figure 3.6: Determining the capture antibody concentration.  
A substantial drop in signal intensity was observed when the capture antibody was 
printed at a concentration of 50 ng/ml compared to 100 ng/ml. Although this is the 
result of a single experiment, it suggests that 100 ng/ml anti-human IgG-Fc was the 
optimal capture antibody concentration for printing antibodies on poly-L-lysine 
slides. 
 
Figure 3.7: Different dilution of IgG used for standard curves.  
The highest two concentrations tested in the dilution series were 125 ng/ml and 1.95 
ng/ml, which were diluted 8 times to produce a standard curve. Using a top 
concentration of 125 ng/ml with a biotinylated anti-human IgG (H & L) as the 
secondary antibody improved the linearity of the IgG standard curve, while using a 
top concentration 1.95 ng/ml did not generate a linear standard curve. 
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3.5.1.3. Using an amplification reagent and HRP-conjugated, goat 
anti-human IgG-Fc as a secondary antibody at different 
concentrations 
The HRP-conjugated, goat anti-human IgG-Fc secondary antibody was diluted to 
1:100,000, 1:200,000, 1:400,000, 1:800,000, and 1:1,600,000. The results (Figure 
3.8, 3.9) showed the 1:400,000 dilution produced saturated spots, whereas the 
1:100,000 and 1:200,000 dilutions showed flat curves, therefore a secondary 
antibody dilution of 1:800,000 was chosen for the IgG standard curve. 
3.5.1.4. IgM and IgA standard curves        
The results (Figure 3.10) showed that when using a high concentration of 500 
ng/ml, the HRP-conjugated goat anti-human IgM-Fc and anti-IgA-Fc were suitable 
as secondary antibodies, and linear standard curves for IgM and IgA were achieved 
with dilutions 1:800,000 or 1:1,600,000, respectively. 
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Figure 3.8: Examining different concentrations of an HRP-conjugated, goat 
anti-human IgG-Fc secondary antibody to improve the IgG standard curve.  
The results were obtained by using four different detection-antibody 
concentrations. (a, b) The 1:100,000 and 1:200,000 dilutions showed flat curves 
and did not show gradually increasing signal intensity. (c) The 1:400,000 dilution 
was marked with saturated spots on the top. (d, e) The 1:800,000 and 1:1,600,000 
dilutions showed good, incremental standard curves. 
 
Figure 3.9: IgG standard curves generated on three different days. A secondary 
antibody dilution of 1:800,000 was chosen for the IgG standard curve. 
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Figure 3.10: Examination of the different concentrations of the HRP-
conjugated goat anti-human IgM and anti-IgA.  
HRP-conjugated goat anti-human IgM-Fc secondary antibody was used to generate 
the IgM standard curve (a), and the HRP-conjugated goat anti-human IgA-Fc 
secondary antibody was used to generate the IgA standard curve (b). Dilutions of 
1:800,000 and 1:1,600,000 were chosen for the IgM and IgA standard curves, 
respectively.  
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3.5.2. Antibody microarray-validation results 
3.5.2.1. Cross-reactivity results 
3.5.2.1.1. Examination of anti-IgG cross-reactivity with IgM and 
IgA, using biotinylated anti-IgG (H & L) as a detection antibody 
Based on the previous results, which yielded linear standard curves with 
biotinylated anti-human IgG (H & L), the cross-reactivity was checked. The results 
showed high cross-reactivity with IgM and IgA (Figure 3.11). 
3.5.2.1.2. Examination of the cross-reactivity for anti-IgG with IgM 
and IgA when using HRP-conjugated goat anti-human IgG-Fc as a 
detection antibody 
Based on the previous results, cross-reactivity was checked to determine the 
specificity of the reagents. An HRP-conjugated goat anti-human IgG-Fc antibody 
(1:800,000) was used as the secondary antibody. 
The results (Figure 3.12 a,b) showed a very good standard curve for IgG without 
any cross-reactivity with IgM and IgA, also, IgD was not detectable. Moreover, 
there was no false-positive detection between the secondary antibody and IgM. This 
result indicated the high specificity of the secondary antibody, as well as the IgM 
and IgA capture antibodies. To ensure reproducibility this experiment was 
performed on 3 different days and the results were averaged. 
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Figure 3.11: Cross-reactivity experiments.  
The biotinylated anti-human IgG (H & L) antibody used showed high cross-
reactivity with IgM and IgA. The irregular distribution of points for IgA is the 
reason for poor fit of the curve.  
  
Figure 3.12 (a): Studying cross-reactivity between IgM, IgA and IgD standards 
with anti-IgG. 
Anti-human IgG was used as the capture antibody, and an HRP-conjugated goat anti-
human IgG-Fc antibody served as the detection antibody. No cross-reactivity was 
observed between the IgM and IgA or IgD standards with an anti-human IgG capture 
antibody and an HRP-conjugated goat anti-human IgG antibody as the detection 
antibody. IgG standard curves were generated on three different days. The values 
for IgD were completely undetectable and therefore do not appear on this figure.  
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Figure 3.12 (b): Studying potential binding between IgG and different capture 
antibodies.  
Different capture antibodies were coated on the slide and incubated with an IgG 
standard and an HRP-conjugated goat anti-human IgG-Fc antibody as the detection 
antibody. The data shown in this figure confirmed that the IgG standard could bind 
only with the IgG capture antibody, but not with the IgM, IgA or IgD capture 
antibodies. The values with IgD capture antibody were completely undetectable and 
therefore do not appear on this figure. 
3.5.2.1.3. Examination of the cross-reactivity for anti-IgM with IgG 
and IgA, as well as that for anti-IgA with IgG and IgM 
The results showed that no cross-reactivity occurred between IgM or IgG with the 
anti-IgA and that the IgA capture and detection antibodies measured only IgA 
(Figure 3.13 a, b). Moreover, no spots developed when applying IgA and IgG 
standards with the anti-IgM antibody and its secondary antibody (Figure 3.14 a,b). 
Additional experiments were performed that included secondary IgG and IgM 
antibodies, or IgA with a secondary anti-IgM antibody. Analysing the slides 
showed that IgG only bound with its capture and detection antibodies. The same 
results were also found with IgA (Figure 3.15), and also, IgD was not detectable. 
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Figure 3.13 (a): Studying the cross-reactivity between IgG, IgM standards and 
IgD with anti-IgA antibodies.  
Using anti-human IgA as a capture antibody, an HRP-conjugated goat anti-human 
IgA as a detection antibody, and different Ig isotypes. The data shown confirmed 
the specificity of the IgA capture and secondary antibodies because the IgM and 
IgG standards were not detected significantly. IgA curves were done on three 
different days. Also, IgD was not detectable and so does not appear in the figure. 
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Figure 3.13 (b): Studying potential binding between IgA and different captures 
antibodies.  
The slide was coated with different capture antibodies, incubated with IgA 
standard, and binding was detected with an HRP-conjugated goat anti-human IgA. 
This experiment confirmed that the IgA standard could bind only with the IgA 
capture antibody, but not significantly with the IgM or IgG capture antibodies. 
 
Figure 3.14 (a): Studying the cross-reactivity between IgG and IgA standards 
with anti-IgM antibodies.  
Using an anti-human IgM as the capture antibody, an HRP-conjugated goat anti-
human IgM as the detection antibody, and different Ig isotypes. The data shown 
confirmed the specificity of the IgM capture and secondary antibodies because the 
IgA and IgG standards were not detected. The curves for IgM standard represent 
three different experiments. 
2 4 8 16 32 64 128 256 512
0
5000
10000
15000
20000
25000
IgA Concentration (ng/ml)
A
rb
it
ra
ry
 f
lu
or
es
ce
n
ce
IgG Capture /IgA st. 
IgM Capture/IgA st.  
IgA Capture/ IgA st.
4 8 16 32 64 128 256 512 1024
0
10000
20000
30000
40000
50000
IgM Concentration (ng/ml)
A
rb
itr
ar
y 
flu
or
es
ce
nc
e
IgM capture/ IgM st.
IgM Capture/IgA st.  
IgM capture/ IgM st.
IgM capture/ IgG st.
IgM capture/IgM st.
Chapter 3                               Optimisation and Validation of Antibody Microarray 
79 
 
 
Figure 3.14 (b): Studying potential binding between IgM and different 
captures antibodies.  
The slide was coated with different captures antibodies, incubated with primary 
IgM, and detected with an HRP-conjugated goat anti-human IgM. The data shown 
in this figure confirmed that the IgM standard could bind only with the IgM capture 
antibody and not to the IgG or IgA capture antibodies. 
 
Figure 3.15: Example of slides used for studying the cross-reactivity of IgG 
and IgA standards with the IgM capture and detection antibodies.  
Every block showed high specificity with the reagents used, as the IgG spots were 
observed only with the IgG capture and detection antibodies, and no spots were 
observed with the IgM capture and detection antibodies. Similar results were 
obtained with IgA. 
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3.5.2.2. Precision test results 
3.5.2.2.1. Intra- and inter-assay variability results  
The coefficients of variation (CV) for the intra-assay tests were calculated for 
several serum samples, and the readings varied by less than 10% for IgG, IgM, IgA, 
and IgD, which was acceptable for studying samples from smokers and non-
smokers in the microarray assay (Figure 3.16). As expected, the inter-assay CVs 
were greater than the intra-assay CVs, and the readings were less than 15 % for 
IgG, IgM, IgA, and for 7 IgD samples (Figure 3.17). These CVs can be accepted 
according to FDA [255].  
 
Figure 3.16: The coefficients of variation (CVs) of intra-assay results were 
calculated for several samples.  
The dashed lines represent the acceptable limit of precision (CV ≤ 10 %). The solid 
lines represent the median for each group. The CV% was <10 % for IgG (a), <9.2 
% for IgM (b), <10 % for IgA (c), and <8.2 % for IgD (d). 
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Figure 3.17: The percent coefficient of variation (CV %) for inter-assay test 
results was calculated for several serum samples.  
The solid lines represent the median for each group. The dashed lines represent the 
acceptable limit of precision (CV ≤ 15 %) for IgG, IgM, IgA, and IgD. 
3.5.2.2.2. Limit of detection (LOD)   
The LOD can be defined as the lowest concentration of analyte that can be reliably 
detected. The LOD was determined for each antibody by calculating the mean and 
standard deviation of the blank from the standard curve, after which the following 
equation was applied: LOD = 2SD (mean of the blank) + mean of the blank (Figure 
3.18). The LOD for IgG was 1685; whereas the LOD for IgM (28), IgA (7), and 
IgD (2447) were all below the lower limit in the standard curves. 
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Figure 3.18: Determining the LLOD for IgG.  
The lower limit of detection (LLOD) for IgG was determined as lowest level of 
analyte that could be measured using the standard curve. LOD = 2SD (mean of the 
blank) + mean of the blank. 
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3.6. Discussion  
 In this chapter, all essential parameters that can affect microarray sensitivity and 
reproducibility were evaluated and optimized. Within this study, the parameters 
optimized included the printing buffer, blocking buffer, and the concentrations of 
the standard and detection antibodies. A commercial ELISA kit was optimised to 
make it suitable for detecting the Ig classes, using a microarray platform. 
Poly-L-lysine slides were chosen for this study based on previous data from our 
group. Another important factor that affects development of an antibody microarray 
is non-specific protein binding, which increases the background and spot signals. 
Therefore, optimization of the blocking buffers I-Block and BSA (with tris-
phosphate and NaCl) was carried out to reduce non-specific binding. By comparing 
the effects of different blocking buffers on the sensitivity and specificity of Ig 
detection, BSA (with tris phosphate and NaCl) was shown to produce the highest-
quality performance when compared to other blocking buffers tested, generating 
regularly shaped spots with a low background, and lacking a tail. Moreover, PBS-
trehalose buffer was effective as a coating buffer for the detection of all the Ig 
isotypes, as it involves a more alkaline medium that enhances anti-human Ig 
binding to microarray slides. Each Ig was investigated using different 
concentrations to generate optimal standard curves, and standard curves for all Igs 
were successfully generated in the microarrays. 
Intensive cross-reactivity experiments were performed in this chapter to identify 
cross-reactivity with the detection antibodies. The optimal concentration of the 
standard antibodies was found to be 500 ng/ml; however, the concentration still 
showed a high level of cross-reactivity when using biotinylated anti-IgG (H & L) 
as the detection antibody. Therefore, additional experiments were performed to 
eliminate cross-reactivity in our antibody microarray platform. These experiments 
involved investigating the effect of using an HRP-conjugated goat anti-human IgG-
Fc. And interestingly, the results showed that no cross-reactivity occurred, which 
could have been due to the ability of all antibodies to recognize light chains when 
use biotinylated anti-IgG (H & L), while the HRP-conjugated detection recognized 
part of heavy chain which is highly specific for each isotype.  Precision was also 
examined in this chapter by assessing the intra- and inter-assay CV %. The results 
showed that the intra-assay variation for all antibody classes was below 10 %, 
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which was acceptable, and the intra-assay on different days was acceptable at <15 
%.  
3.7. Conclusions 
The use of microarray technology is currently increasing. This chapter details the 
optimization and validation of an antibody microarray using very specific and 
accurate reagents, which are able to detect IgG, IgM, IgA, and IgD classes in large 
numbers of samples.  As shown in the next chapter, the antibody microarray was 
used to test 100 samples, but this could be expanded to include more samples and 
in a high throughput manner. The results of this chapter demonstrated that the 
developed microarray could identify the isotype of multiple samples relatively 
easily, with a smaller sample volume than required for the equivalent standard 
ELISA assay and with a greater dynamic range of detection. As both the accuracy 
and reproducibility of the microarrays were acceptable, serum and saliva samples 
were analysed in microarrays to study differences between samples from smokers 
and non-smokers, as described in the next chapter. 
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4. Comparing Antibody-Microarray Data from Smokers 
and Non-Smokers 
4.1. Introduction 
The chronic inhalation of cigarette smoke changes immunological functions by 
impacting both innate and adaptive immunity. The incidence of many diseases 
could be associated with the adverse effects of cigarette smoke on the immune 
system, which may cause inflammatory responses and affect the tissues and bodily 
organs. Therefore, a comparison of smokers and non-smokers immunoglobulin 
levels can provide critical insights into the mechanisms of smoking-related 
diseases. Although the effects of cigarette smoking on humoral and cellular 
immunity have been investigated, variable results have been reported in these 
studies, and additional studies should be performed [123, 186]. The microarray 
technique has been used in the present study to provide novel insights into the 
pathogenesis of smoking-related diseases.  
4.2. Materials and methods 
4.2.1. Procedure for serum and saliva collection 
Serum and saliva were collected from 48 smoking (median age = 30 years; age 
range 19-51) and 48 non-smoking (median age = 32.5 years; age range 20-56) male 
blood bank volunteers at King Abdulaziz Hospital, Jeddah, Saudi Arabia. The 
samples were aliquoted in eppendorf tubes and stored at -20oC. They were 
transported on ice to Queen’s Medical Centre, Nottingham, UK, and then stored 
frozen until assayed. Ethical approval was granted by The Biomedical Research 
Ethics Committee, Ministry of Higher Education, King Abdulaziz University, 
Faculty of Medicine (a copy of the approval letter is appended).  
4.2.1.1. Collection of demographic data on the subjects 
Tables 4 and 5 show demographic information for the male smoker subjects. Non-
smoking male subjects were age-matched with the smoking subjects, who had an 
average age of 30 years – there are no significant differences in the age between the 
two groups.  The demographic information on age, years smoked and number of 
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cigarettes smoked per day were self-reported by each subject and recorded on a 
standardised form. The non-smokers could be passive smokers, but reported that 
they had never actively smoked. 
4.2.1.2. Serum collection 
Smoker and non-smoker donors were requested to provide 10 ml of blood after 
signing an informed-consent form. Blood samples were collected in plain serum 
separation tubes (BD Vacutainer™ Venous Blood Collection Tubes: SST™ Serum 
Separation Tubes: Hemogard); these tubes contain a special gel that separates blood 
cells from serum (Thermo Fisher Scientific). The tubes were centrifuged at 2000g 
for 10 minutes. Serum samples were aliquoted and stored immediately at -20oC. 
4.2.1.3. Unstimulated saliva collection 
Consenting donors (smokers and non-smokers) were requested to provide 
approximately 5 ml of saliva, which was collected over a period of 5-10 minutes. 
Donors ceased from eating and drinking for at least 1 hour prior to donation. After 
cleaning the mouth with mouthwash and rinsing with water over 5 min, donors 
provided saliva into plain separation tubes (Thermo Fisher Scientific) and the tubes 
kept on ice. Then, the saliva samples were centrifuged at 2600g for 15 minutes at 
4°C. Samples were aliquoted and immediately frozen at 20 °C.  
4.2.2. Assaying serum and saliva samples  
Several serial dilutions of serum and saliva samples from healthy smokers and non-
smokers were tested to determine the optimal dilutions for measuring each Ig class. 
The arbitrary fluorescence of each saliva and serum sample was compared to the 
standard curve of the serial dilutions for the specific Igs, as developed in the 
previous chapter.  
To measure serum Ig levels, sera were diluted 1:100, 1:1,000, 1:20,000, 1:40,000, 
1:100,000, and 1:500,000 in reagent diluent. Saliva was diluted to 1:1, 1:2, 1:10, 
and 1:1000 in the same reagent diluent.  
4.2.3. Applying serum and saliva samples  
 Following a typical procedure for generating standard curves for each Ig tested in 
microarray format, the arbitrary fluorescence readings for serum and saliva samples 
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were interpolated with the standard curves, and their concentrations were calculated 
using Graphpad Prism 6. 
 
Table 4.1: Demographics of the smoker subjects (a).  
The information in this table was self-reported. 
Number Gender Age 
Number of 
cigarettes 
per day 
Full 
inhalation 
of smoke/ 
Filter 
Tobacco 
product 
Years 
smoked 
1 Male 32 10-12 yes/yes Yes 15 
2 Male 27 21 yes/yes Yes 7 
3 Male 33 10-20 yes/yes Yes 15 
4 Male 25 15 yes/yes Yes 7 
5 Male 34 5-10 yes/ no Yes 10 
6 Male 28 20 yes/ no Yes 8 
7 Male 47 < 10 yes/yes yes 20 
8 Male 34 40 yes/ no Yes 18 
9 Male 26 20 yes/ no Yes 4 
10 Male 28 15 yes/ no Yes 10 
11 Male 31 35-40 yes/ no Yes 10 
12 Male 30 30 yes/ no Yes 16 
13 Male 56 20 yes/ no Yes 25 
14 Male 28 30 yes/ no Yes 13 
15 Male 20 20 yes/ no Yes 5 
16 Male 24 20 yes/ no Yes 7 
17 Male 25 20-30 yes/ no Yes 9 
18 Male 22 1 yes/ no Yes 2 
19 Male 24 6-7 yes/ no Yes 4 
20 Male 21 1 yes/ no Yes 5 
21 Male 25 40 yes/ no Yes 8 
22 Male 28 20 yes/ no Yes 8 
23 Male 33 12 no/no Yes 12 
24 Male 36 20-40 yes/ no Yes 10 
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Table 4. 2: Demographics of the smoker subjects (b).                                       
The information in this table was self-reported. 
 
Number Gender Age 
Number of 
cigarette 
per day 
Full 
inhalation 
of smoke/ 
Filter 
Tobacco 
product 
Years 
smoked 
25 Male 33 20 yes/yes Yes 33 
26 Male 26 12-20 yes/no Yes 10 
27 Male 23 20 yes/no Yes 6 
28 Male 28 20 yes/no Yes 10 
29 Male 23 20 yes/no Yes 5 
30 Male 38 20 yes/no Yes 20 
31 Male 33 20 no/no Yes 15 
32 Male 37 20 yes/no Yes 14 
33 Male 30 4 yes/no Yes 6 
34 Male 29 30 yes/no Yes 6 
35 Male 20 30 yes/no Yes 6 
36 Male 30 24 yes/no Yes 12 
37 Male 23 25 yes/no Yes 8 
38 Male 46 20 yes/no Yes 30 
39 Male 30 20 yes/no Yes 14 
40 Male 29 15 yes/no Yes 5 
41 Male 44 20 yes/no Yes 8 
42 Male 26 20 yes/no Yes 12 
43 Male 35 20 yes/no Yes 15 
44 Male 28 20 yes/no Yes 7 
45 Male 36 20 yes/no Yes 15 
46 Male 45 20-25 yes/ no Yes 12 
47 Male 30 5-20 yes/ no Yes 16 
48 Male 36 10 yes/ no Yes 10 
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4.3. Results 
The overall distribution of serum Ig levels in the population was investigated using 
DAgostino–Pearson omnibus normality test dependent on a Gaussian distribution, 
showed a non-normal distribution of IgA, IgG, IgM, and IgD. 
4.3.1. Serum and saliva dilution-series results 
Figure 4.1 shows a serum dilution of 1:40,000 was found to be optimal for 
measuring IgG and IgA, while a 1:200 dilution was optimal for IgM and IgD. In 
addition, a 1:2 dilution was suitable for detecting salivary Igs. 
4.3.2. Serum sample results 
The results (Figure 4.2) obtained for the serum samples from smokers and non-
smokers, were compared using a Mann–Whitney test (2-tailed). Significant 
differences in the Ig levels were observed between the 2 groups in terms of IgG and 
IgD levels, which were lower in smokers than in non-smoker subjects (P < 0.0001, 
P < 0.05, respectively). However, IgM and IgA levels were significantly higher in 
smokers than in non-smoker subjects (P < 0.0001, P < 0.05, respectively). 
4.3.3. Saliva samples results 
The results (Figure 4.3) obtained for the saliva samples from smokers’ and non-
smokers’ were compared using a Mann-Whitney test (2-tailed). Significant 
differences were observed in the Ig levels between the 2 groups, IgG (P < 0.05) and 
IgM (P < 0.0001) levels were lower in smokers than in non-smokers. IgA levels 
were higher in smokers than in non-smokers (P < 0.05) levels, and no significant 
differences were observed in their IgD levels. 
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Figure 4.1: Determination of a suitable serum dilution.  
The interpolated samples with a dilution of 1:40,000 fit in the middle of the curves 
for IgG and IgA, and a 1:200 dilution was used to measure IgM and IgD. 
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Figure 4.2: Comparing the Ig concentrations in serum samples from smokers 
and non-smoker subjects using a Mann–Whitney test revealed significant 
differences.  
(a) Serum IgG concentrations were lower in smokers than in non-smoker subjects 
(p < 0.0001). (b) IgM concentrations were higher in smokers than in non-smoker 
subjects (P < 0.0001). (c) IgA concentrations were higher in smokers than in non-
smoker subjects (P < 0.05). (d) IgD concentrations were lower in smokers than in 
non-smoker subjects (P < 0.05). 
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Figure 4.3: Comparing Ig concentrations in saliva samples from smokers and 
non-smoker subjects using a Mann–Whitney test revealed significant 
differences.  
(a) IgG concentrations were lower in smokers than in non-smokers (P < 0.05). (b) 
IgM concentrations were lower in smokers than in non-smokers (P < 0.0001). (c) 
IgA concentrations were higher in smokers than in non-smokers (P < 0.05). (d) IgD 
concentrations were not significantly different between smokers and non-smokers. 
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4.3.4. Studying correlations between serum immunoglobulins 
Figure 4.4 and figure 4.5 show the assessment of correlations between serum Ig 
levels for smokers and non-smokers, respectively. The Spearman coefficient 
correlation (2-tailed) was calculated for every 2 Ig isotypes in the serum samples. 
Only IgG and IgA from smokers showed a significant positive correlation (P  
0.05). 
4.3.5. Studying correlations between saliva immunoglobulins 
The correlations between saliva Ig levels were investigated using the Spearman 
coefficient correlation (2-tailed), which was calculated for every combination of 2 
Ig isotypes in the saliva samples for smokers (Figure 4.6), and non-smokers subjects 
(Figure 4.7). The results (Figure 4.6) show that only IgG and IgA from smokers’ 
saliva showed a significant positive correlation (P  0.05).  
4.3.6. Studying correlations between serum and saliva 
immunoglobulins  
The Spearman coefficient correlation (2-tailed) was calculated for each of the Ig 
isotypes in the saliva samples vs serum samples from the same individuals. There 
were no significant correlations between Ig isotypes for the smokers’ (Figure 4.8) 
or non-smokers (Figure 4.9) in these samples.  
4.3.7. Correlation between immunoglobulin levels and smoking 
pack-years  
To study the relation between serum Ig levels and smoking pack-years, the 
Spearman correlation coefficients (2-tailed) between each Ig class and smoking 
pack-years were calculated (Figure 4.10), and the Spearman correlation coefficients 
(2-tailed) for each saliva Ig isotype and smoking pack-years were calculated (Figure 
4.11). These tests showed that the serum and saliva Ig levels were not significantly 
correlated with the smoking pack-years.  
 
Chapter 4  Comparing Antibody-Microarray Data from Smokers and Non-Smokers 
94 
 
 
Figure 4.4: The Spearman correlation coefficient (2-tailed) between paired Ig 
isotypes for smoker’s serum samples.  
The results showed that the only significant positive correlation occurred between 
IgG and IgA (P  0.05). 
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Figure 4.5: The plot of the Spearman correlation coefficient (2-tailed) between 
paired Ig isotypes for non- smoker’s serum samples.  
The results showed there are no significant correlations between immunoglobulin 
concentrations in the samples. 
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Figure 4.6: The plot of the Spearman correlation coefficient (2-tailed) between 
paired Ig isotypes for smokers’ saliva samples.  
The results showed that the only significant positive correlation occurred between 
IgG and IgA (P  0.05). 
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Figure 4.7: The plot of the Spearman correlation coefficient (2-tailed) between 
paired Ig isotypes for non-smokers saliva samples.  
The results showed there are no significant correlations between immunoglobulin 
concentrations in the samples. 
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Figure 4.8: The plot of the Spearman correlation coefficient (2-tailed) between 
Ig isotypes in saliva and serum samples for smoker’s subjects.  
The results showed there are no significant correlations between immunoglobulin 
concentrations in the samples. 
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Figure 4.9: The plot of the Spearman correlation coefficient (2-tailed) between 
Ig isotypes in saliva and serum samples for non-smoker’s subjects. 
The results showed that the serum Ig levels were not significantly correlated with 
the saliva Ig levels. 
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Figure 4.10: Studying the relation between serum Ig levels and smoking pack-
years.  
The Spearman correlation coefficients (2-tailed) for each Ig and smoking pack-
years were calculated. The results showed that serum Ig levels were not 
significantly correlated with the smoking pack-years.  
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Figure 4.11: Studying the relation between saliva Ig levels and smoking pack-
years.  
The Spearman correlation coefficients (2-tailed) for each Ig and smoking pack-
years were calculated. The results showed that the serum Ig levels were not 
significantly correlated with the number of pack years of smoking.  
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4.4. Discussion 
Tobacco smoke contains numerous harmful components, such as oxidants and pro-
oxidant compounds, which are efficient in generating free radicals and increasing 
oxidative stress [187, 188]. In fact, over 4000 different chemicals are released in 
tobacco smoke. These components include carbon monoxide, hydrogen cyanide, 
phenols, ammonia, formaldehyde, benzene (a) pyrene, nitrosoamines, nicotine, tar, 
heavy metals, radioactive products, poisons, and at least 48 known cancer-
generating compounds [1, 189]. These harmful components not only affect active 
smokers, but also affect passive and involuntary smokers who inhale the smoke 
particulates from the environment [190]. It can be thought that long-term 
involuntary smoking may manifest with similar medical problems in active smokers 
[187]. Cigarette smoking is well known for its adverse health influences, and is 
considered a major risk factor for developing cancers, as well as cardiovascular and 
respiratory diseases. The dangerous effects of cigarette smoke include an increased 
risk for atherosclerosis [191, 192], coronary heart disease, and various neoplastic 
disorders, including lung cancer [192, 193]. There is evidence to indicate that 
maternal smoking during pregnancy leads to detrimental alterations in the placenta 
and fetus accompanied with low birth weight and increased risk of abortion and 
neonatal mortality in one-third in women who smoke during pregnancy compared 
with non-smoking women. Thus, increased risk of intrauterine growth retardation, 
prematurity, stillbirth and sudden infant death syndrome have been well recognized 
[194, 195]. It is also important to recognise that deleterious effects of smoking on 
infants after birth may be associated with the inhalation of cigarette smoke 
generated by other household members in addition to the mother. Studies have 
reported that cigarette smoking is one of the key mutagenic factors that can lead to 
damage to human genetic material. Thus, an improved understanding of the 
mechanisms whereby cigarette smoke negatively impacts human health is 
paramount, given its addictive nature and chronic cigarette-smoking consequences 
[196, 197]. Previous studies have revealed some effects that can explain the 
dangerous effects of tobacco smoke, such as its oxidative damage, the increased 
oxidation of LDLc, and elevated levels of fibrinogen, C-reactive protein (CRP), and 
uric acid [191, 198]. In addition, active cigarette smoking is associated with 
prognostic biochemical features of cardiovascular diseases, such as CRP elevation, 
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raised lipid peroxidation, inflammation, and variations in anti-oxidative enzyme 
activities [199, 200]. Therefore, the early detection of altered biochemical 
components in the body can be used as predictive biomarkers for smoking-related 
diseases. Even though the blood is considered a major source of biomarkers for 
diagnosing diseases, the saliva can also reflect the mucosal and systematic 
expression of analytes and give insights into disease diagnosis. Salivary Igs are 
derived from 2 sources: the salivary glands and the serum. Secretory IgA (sIgA) is 
produced by local plasma cells in the salivary glands and serves vital roles in the 
immune defence mechanisms that are active in the saliva. The minor salivary glands 
serve a crucial function in sIgA-mediated immunity of the oral cavity, and the cells 
in the parotid and submandibular glands are responsible for most the IgA found in 
saliva. 77 % of monomeric IgA in saliva is derived from the serum. In contrast, IgM 
and IgG in the saliva mainly originate from the serum, and some IgG might be 
locally produced in the gingiva and salivary glands. IgM and IgG exist in a lower 
abundance in saliva than does IgA [201]. The levels of salivary antibodies can 
reflect previous viral infections and can be used to diagnose viral infection, 
congenital infections, and reactivation of infection [202].  
For my project, we hypothesized that smoking contributes to diseases through its 
effects on immune responses, inflammation, and Ig levels. Therefore, the purpose 
of this study was to compare Ig class levels in serum and saliva samples from 
smokers and non-smokers, as alterations in their production levels may yield 
valuable insights into the underlying mechanisms of smoking-related diseases, and 
also provide additional information useful for clarifying the basis of the toxic 
effects of cigarette smoking. To our knowledge, this is the first study to use a high-
specificity microarray platform to compare the levels of Ig classes in serum and 
saliva samples from smokers and non-smokers. The microarray was optimised and 
validated using several tests, which facilitated the accurate and specific 
measurement of Ig levels. 
Although the effects of cigarette smoking on the humoral system have been 
investigated previously, variations are apparent in the results obtained in different 
studies, and more research should be conducted on this subject. In terms of IgG, 
Charu Shrestha et al. (2014) showed that the long-term effects of smoking could 
lead to significant decreases in serum IgG levels. Smokers were found to have lower 
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serum IgG levels than observed in healthy control subjects and non-smokers with 
chronic periodontitis. In addition, it was shown that cigarette smoking could cause 
the suppression of B cell functions and the subsequent production of Igs. Therefore, 
the authors suggested that alterations in the levels of antibodies can explain the 
aggravations found in periodontal disease [203]. IgG levels were also lower in 
smokers with rheumatoid arthritis [204]. Another study also found that healthy 
smokers have lower serum IgG levels than do non-smoking individuals; however, 
no differences were found in the levels of serum IgA and IgM [133]. A previous 
study that focused on comparing the effects of smoking and alcohol consumption 
on serum Ig concentrations reported that alcohol consumption correlated with a 
significant increase in serum IgA levels, while the serum IgG and IgM levels 
decreased. However, the decrease in serum IgG levels, and to lesser extent IgM 
levels, was observed only in smokers. Further, smoking caused a decreased 
concentration of all Ig isotypes, and in a group who did not consume alcohol, 
smoking significantly correlated to decreased IgG concentrations [205]. Previous 
data showed that serum Ig concentrations tended to be lower in nicotine-consuming 
subjects, with IgG4 being significantly decreased in this group [206].  
Arinola et al. (2013) reported that active cigarette smokers had elevated levels of 
serum IgG and IgM, compared with those observed in never-smokers. The authors 
explain that IgG and IgM promote activation of the complement system, which is 
essential for phagocytosis, microbe lysis, and toxin neutralization [207]. 
Considering that cigarette smoke contains many toxic components, the noted 
increase in IgG and IgM levels likely reflects an important mechanism in 
neutralising toxic tobacco components through complement-activation [187]. Other 
findings showed that smoking can increase the risk for oral infection with human 
papilloma virus and correlated with elevated levels of salivary IgG and lysozyme 
[208]. In a separate study, it was found that in a group of people who quit smoking, 
the quantity of lymphocytes decreased and NK activity against cultured melanoma 
cells increased. In addition, their serum IgG and IgM concentrations were 
significantly increased. Although there was no effect on the serum IgA 
concentration, the salivary IgA and IgG concentrations increased after smoking 
cessation. The NK activity and Ig concentrations showed no significant differences 
in the smoker group relative to that observed in the non-smoking group. Therefore, 
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these results demonstrated an inverse correlation between smoking status and 
immune function. These results may offer insights into the relationship of smoking 
status with an increased prevalence of certain malignant diseases and respiratory 
infection [209]. With respect to IgM levels, previous findings have indicated that 
no significant differences occur in serum IgM levels between smokers and non-
smokers [138]. In addition, some research has indicated that significant increases 
occur in salivary IgM levels in smokers, compared with that observed in non-
smokers, which may have an enhanced effect when combined with the low levels 
of salivary IgA [210]. The results from many studies have indicated that, in 
stimulated saliva (i.e. induced by chewing paraffin wax), individuals who have IgA 
immunodeficiency have increased IgM levels [129]. In terms of IgA, Barton et al. 
(1990) reported that in healthy individuals from Cairo, salivary IgA levels were 
lower in smokers compared to non-smokers, whereas salivary IgM levels were 
higher in smokers; salivary IgG levels were the same between smoking and non-
smoking individuals; and no significant differences occurred between their levels 
in saliva. In addition, a strong negative correlation was observed between IgA levels 
and the number of cigarettes smoked per day. However, no relationship was 
identified between the salivary IgG or IgM levels and the number of cigarettes 
smoked per day. In addition, the effects of smoking cessation on Ig levels were 
studied, and it was found that differences in IgA levels were reversed after smoking 
cessation. It was also found that the salivary IgA levels in ex-smokers (for 2 years), 
who had been smoking 20 cigarettes per day, were higher than in current-smoker 
subjects. Moreover, 5 years later, the levels of salivary IgA were equivalent to those 
in non-smoker subjects. However, at 2 years post-smoking cessation, the levels of 
salivary IgM did not differ significantly from those of non-smokers. Nonetheless, 
at 5 years post-cessation, the IgM levels were significantly higher than in non-
smokers [126]. Similar research conducted by a group in Edinburgh indicated that 
healthy smokers and patients with head and neck tumours, the majority of which 
were smokers, had lower salivary IgA and higher salivary IgM concentrations 
compared with those found in healthy non-smoking subjects. These data provide 
evidence regarding the effect of smoking on mucosal immunity. Based on the 
simple concept that IgM has very different properties compared to IgA, the increase 
in IgM levels could be interpreted as a compensatory action, and its elevated levels 
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could reflect immunopathology rather than naive compensation. We have not yet 
addressed the mechanism whereby cigarette smoking alters the Ig profile in saliva. 
Smoking, however, could impair the immune regulation of T cells on B cell 
differentiation and maturation. Alternatively, a study of the effects of cigarette 
smoking on cervical epithelial immunity showed that the variations can occur 
through gut antigen presenting cells in the afferent limb of immunity, as recently 
reported for uterine cervical epithelium. These authors assumed that an indirect 
mechanism was involved because the cervix and parotid gland are distant from the 
nearest sites directly affected by cigarette smoke. In addition, the effects of smoking 
show variation depending on whether an individual is a light, moderate, or heavy 
smoker [126, 211, 212]. Moreover, data from a previous study showed that tobacco 
smoking does not affect the compensatory rise in salivary IgG responses to an IgA 
deficiency in smoking and non-smoking individuals. According to a previous 
examination of salivary IgA in mixed unstimulated saliva, tobacco smokers showed 
decreased levels of salivary IgA when compared with that observed in the normal 
group [126, 127]. Conflicting evidence, however, has shown that no significant 
differences occur in salivary IgA and IgG, while salivary IgM was significantly 
lower in a smoking group compared to that in a non-smoking group [131]. Lie et 
al. (2002) reported similar levels of salivary IgA between smokers and non-smokers 
participating in a gingivitis trial [132]. Giuca et al. (2014) compared salivary Ig 
levels between smokers and non-smokers versus their periodontal disease status, 
and they reported that smokers have lower saliva IgA, IgG, and IgM levels, as well 
as worsened periodontal conditions than non-smokers. Although there is little 
evidence that salivary Igs exert a protective effect against periodontitis and that not 
all saliva components are produced by the salivary glands, it can be concluded that 
the worsened periodontal health conditions of these patients can be attributed in 
part to decreased protection resulting from a reduction in the quantity of salivary 
Igs [213].  
The levels of serum IgG and IgM were reported to increase significantly after 
smoking cessation, but serum IgA levels remained similar. However, salivary IgG 
and IgA levels rose after smoking cessation [209]. Contradictory evidence indicates 
that no significant difference occurred in serum IgA levels between smoking and 
non-smoking individuals [134]. Indeed, reduced IgA levels were detected in 
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bronchoalveolar lavage fluid (BALF) in smoking individuals [63]. Conversely, 
other evidence indicated that enhanced levels of IgA were present in the BALF 
[136, 214]. In addition, the salivary IgA levels showed a gradual reduction from 
controls to smokers, which may be used as a diagnostic marker in smokers and 
patients with recurrent aphthous ulcers [128]. Richmond et al. (2014) reported that 
patients with COPD who still smoked lacked sIgA, which could lead to enhanced 
COPD pathogenesis and likely rendered the epithelium more vulnerable to damage 
[215]. Results from a study performed to evaluate the levels of salivary IgA in 
tobacco chewers, tobacco smokers, and a control group showed that in unstimulated 
whole saliva, the IgA levels decreased more in tobacco users than in control group, 
and tobacco smokers had much lower salivary IgA levels compared to tobacco 
chewers [216]. A study conducted in 2015 found that in the lungs, cigarette smoke 
may delay quick mucosal IgA responses and enhance the severity of influenza viral 
infection via inhibition of BAFF, a cytokine essential for B cell production and 
maturation [217]. Prior research has also shown that cigarette smoking is an 
essential factor in the development of IgA nephropathy, where IgA accumulates 
and damages the kidneys, and smoking cessation should be considered for patient 
treatment and recovery [218]. Several studies have provided evidence that serum 
IgA levels are lower in smokers than in non-smokers by 10–20 % [123, 124]. 
Moreover, serum IgA levels are higher in healthy smoking individuals, compared 
with patients with COPD that also smoke [130]. 
With regards to IgD, previous research has shown that, in cigarette smokers, the 
levels of serum IgD are twice as high as in non-smokers. However, their levels 
return to normal after smoking ceases. Other studies have provided evidence that, 
in COPD patients, the levels of IgD in serum and nasal secretions are higher than 
those in control individuals. These findings suggest that reduced IgD levels may be 
related to a slowed progression of COPD. In contrast, salivary IgD levels do not 
show significant differences between smokers and non-smokers [141].  
The results shown in this chapter demonstrated that significant differences occur 
between Ig levels in smokers and non-smokers. In serum samples, the IgG and IgD 
levels of smokers were lower than those of non-smoker subjects, while IgM and 
IgA levels were higher in smoker subjects. In addition, the results obtained with 
saliva samples showed the same patterns, except for the IgM levels, which were 
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lower in smokers than in non-smokers. The increased serum IgM in smokers could 
help to neutralize cigarette smoke toxins, as suggested by Arenolate 2013. We can 
suggest that cigarette smoke may inhibit class switching to IgG production, 
therefore there would be more IgM in the smokers’ serum samples and less IgG.  
Alternatively, CS may preferentially promote class switching to IgA rather than 
IgG, consistent with inflammatory effects of CS on the respiratory mucosa and our 
observation of raised IgA levels in both the serum and saliva of smokers.  CS might 
also promote increased activation of naïve B cells, which would help to account for 
the increased serum levels of IgM in smokers. Conversely, the levels of IgM were 
lower in the saliva of smokers than the non-smokers, which might be a 
compensatory effect for the increased levels of salivary IgA.  IgM diffuses into 
secretions at a much lower rate that IgA, and is also more susceptible to enzymatic 
cleavage. Thus, it may be that cigarette smoke has an immediate effect on the upper 
part of the respiratory tract, which is exposed directly to CS and that leads to 
changed salivary antibody levels, and consequently this can cause respiratory 
inflammation and disease. Collectively, our data indicate that cigarette smoking 
suppressed B cell secretion and impaired humoral immunity. Consequently, the IgG 
and IgD levels decreased, and therefore CS may have different effects in B cells, 
leading to different IgM levels in the saliva and serum. 
As discussed above, different studies have reached different conclusions about the 
effect of smoking on Ig class levels.  Our findings are consistent with those of some 
of these previous studies, but differ from others.  Clearly, a range of variables may 
influence the observed effects of CS on Ig levels.  These include the nature and 
conditions of the assays used.  Advantages of our study, using protein microarrays, 
is the ability of this technique to be used to assay large numbers of samples 
simultaneously, thereby reducing inter-assay variation; also, the large dynamic 
range of signal detection means that the Ig levels can be accurately measured over 
a wide range of concentrations without loss of sensitivity at the highest and lowest 
concentrations.  Furthermore, the ability to perform many sample replicates 
simultaneously and to exclude poor-performing replicates in the microarray based 
on defined and valid exclusion criteria (e.g. spot circularity, pixel density, etc.) 
improves the accuracy and reliability of this technique [219, 220]. 
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4.5. Conclusions 
The mechanism whereby smoking affects Ig concentrations remains incompletely 
understood. Prior research has provided evidence that Ig levels (particularly IgG 
levels) decreased with increased smoking, and these effects were reversible after 
smoking cession [205, 206, 209, 221].  Currently, it remains unclear which 
constituents of cigarette smoke are responsible for these effects; however, nicotine 
has been implicated as a key factor in animal and in vitro studies [206, 222, 223]. 
Our findings demonstrated that cigarette smoking caused alterations in serum and 
saliva Ig levels; thus, smoking causes both systemic effects and effects in the oral 
mucosa. These findings shed insight into how smoking causes diseases through 
altering B cell secretions. 
Overall, the IgM levels increased in the serum of smokers, which may help to 
neutralize the toxic components in cigarette smoke, but an altered immune response 
caused a decrease in both the IgG and IgD levels in the smokers. This could be 
because CS inhibits the mechanism of class switching. In addition, CS is a main 
cause for lung disorders, which could explain the increased IgA levels in the serum 
and saliva of smoker subjects. On other hand, our finding concluded that CS caused 
a decreased level of IgM in saliva, which could be related to the compensatory 
balance between IgM and IgA. However, whether Ig levels are affected in vitro in 
response to CSE or nicotine in a similar manner to that seen in smokers is not clear, 
as to date, no in vitro studies relating to this issue have been reported. Therefore, to 
investigate the mechanism of action of CSE on Ig secretions, and whether it has a 
similar impact on Ig secretions when CS is exposed directly to B-cells alone or 
indirectly in the presence of other immune cells such as T cells and antigen 
presenting cells, we decided to conduct a preliminary in vitro study with isolated B 
cells and peripheral blood mononuclear cells (PBMCs). 
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5. Studying the Effects of CSE/Nicotine on B-cell 
Secretions in vitro 
5.1. Introduction 
The constituents of cigarette smoke enter the human body through the pulmonary 
alveoli and then enter the bloodstream and become distributed to all tissues via 
capillary vessels. The particulates in smoke can affect cells within blood, such as T 
cells, B cells, and monocytes, which can then exert systemic effects on other organs. 
The results of previous studies have shown that smoke particulates cause up-
regulation of many nicotine receptors on the surface of B cells [72, 224].  
In addition, long-term exposure to nicotine can inhibit the proliferation and 
development of B cells, which then reduces antibody secretions [74]. As a result, 
smoking is the main agent promoting the development of some diseases, such as 
COPD and emphysema and the dysregulation of B cell functions may play a 
contributing role. Moreover, previous data have indicated that smoking can lead to 
carcinogenesis, as well as respiratory diseases in women (more than in men) [225-
227]. In addition, smoking can impair the fertility of women and lead to early 
menopause [228, 229]. In vitro, PBMCs have been used to study the effects of 
cigarette smoke on immune cells and their gene expression [230-232]. In vivo, the 
influence of cigarette smoking in females on circulating B cells resulted in the 
inhibition of ICOSLG, TCF3, and VCAM1 gene functions [75].  
Following the analysis of Ig concentrations, which revealed that variations in their 
levels are associated with cigarette smoking, we became interested in examining 
the in vitro effects of CSE on antibody secretion from stimulated B cells. B cells 
were stimulated in both T-cell-dependent and -independent manners. 
5.2. Materials and methods  
5.2.1. Materials 
The materials used for the in-vitro experiments are summarized in Table 5.1. 
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Table 5.1: List of materials used for in vitro experiments. 
Materials Sources 
Ethylene diamine tetra-acetic acid 
(EDTA) Sigma-Aldrich 
Foetal bovine serum (FBS) Sigma-Aldrich 
Histopaque-1077 Sigma-Aldrich 
L-glutamine Sigma-Aldrich 
70 % ethanol Sigma-Aldrich 
Trypan blue Sigma-Aldrich 
Negative B cell isolation kit 
Miltenyi Biotec GmbH (Bergisch Glad- bach, Germany) 
(Cat. no. 130-091-151) 
MACS buffer 
50 ml phosphate- buffered saline (PBS), 200ul 
ethylenediaminetetra-acetic acid (EDTA) and 830ul of 
30 % l BSA 
BSA Sigma-Aldrich 
Biotin-Antibody Cocktail (Cocktail 
of conjugated monoclonal antibodies 
against CD2, CD14, CD16, CD36, 
CD43, and CD235) 
Miltenyi Biotec GmbH  
(Bergisch Gladbach, Germany) 
Hanks’ Balanced Salt Solution Sigma- Aldrich 
LS separation column Miltenyi Biotec 
RPMI-1640 medium Sigma-Aldrich 
HEPES Sigma-Aldrich 
Penicillin Sigma-Aldrich 
5.2.2. Methods 
5.2.2.1. Isolation of PBMCs 
Buffy coat were obtained from anonymous blood donations via the Regional Blood 
Transfusion Service (Sheffield), who provided ethical approval, within 24h of 
collection. PBMCs were isolated from 50 ml buffy coat samples diluted into 150 
ml PBS and mixed well. Then, the blood samples were transferred slowly using a 
syringe attached to a filling tube into 6 sterile 50-ml centrifuge tubes each 
Chapter 5             Studying the Effects of CSE/Nicotine on B-cell Secretions in vitro 
112 
 
containing 10–15 ml Histopaque (Histopaque-1077; Sigma-Aldrich, Irvine, UK). 
The blood samples were then centrifuged at 800  g for 30 min. Subsequently, the 
white blood cell layer was collected with a sterile Pasteur pipette and placed into 
new sterile tubes, and 25 ml Hank’s Balanced Salt Solution was used to wash the 
cells (Hanks 123K2368; Sigma-Aldrich, Irvine, UK). The samples were centrifuged 
again at 800  g for 10 min, and the supernatant was discarded. Then, the samples 
were washed twice in PBS with centrifugation at 300  g for 10 min, after which 
they were counted. 
5.2.2.2 Cell counting of viable cells 
First, a haemocytometer slide was cleaned with 70 % ethanol. Then, 10 l of cells 
and 10 l of Trypan blue were mixed and pipetted onto the haemocytometer slide 
and covered. Trypan blue was used to selectively colour dead cells blue. The slide 
was placed under a microscope, and the mean numbers of cells in three large 
squares containing 4 smaller squares each were counted. The concentration of cells 
in the original sample was calculated as follows: 
Number of cells/ml = number of cells counted x dilution factor x 104 
5.2.2.3. Magnetic separation of B cells 
To separate B cells, isolated PBMCs were subjected to immunomagnetic negative 
selection of B-lymphocytes, using the Negative B Cell Isolation Kit from Miltenyi 
Biotec GmbH (Bergisch Gladbach, Germany) (Catalogue No. 130-091-151). 
Briefly, the cell pellet from the previous step was resuspended in cold MACS buffer 
(50 ml PBS, 200 l EDTA, and 830 l of 30 % l BSA; Sigma-Aldrich, Irvine, 
UK) at a ratio of 40 l /1  107 cells. Then, Biotin-Antibody Cocktail (cocktail of 
biotin-conjugated monoclonal antibodies against CD2, CD14, CD16, CD36, CD43, 
and CD235a [glycophorin A]) was added at a ratio of 10 l/1  107 total cells. Next, 
the samples were incubated for 5 min in a refrigerator (2–8 ºC). Subsequently, 30 
l MACS buffer and 20 l Anti-Biotin Micro Beads were added/1  107 total cells, 
and the suspension was incubated for an additional 10 min in the refrigerator (2–8 
ºC). Then, the cell suspension was resuspended in 1 ml MACS buffer and loaded 
onto a cold LS separation column (Catalogue No. 120-000-472; Miltenyi Biotec). 
Magnetic cell sorting was initiated after setting the magnet on the holder and the 
column on the cold magnet. A 3 ml LS column was equilibrated with MACS buffer, 
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and the cells were then passed through the column. The column was rinsed 3 times 
with 3 ml LS column MACS buffer to elute the B cells. After the third wash, the 
column was removed from the magnet and placed in a new sterile tube, and 3 ml 
MACS buffer/LS column was added and plunged through to remove the remaining 
leukocytes. The B cell samples were then centrifuged at 300  g for 5 min to remove 
the MACS buffer. Finally, the B cells were resuspended at a concentration of 1  
106/ml in RPMI 1640 complete medium (Catalogue No. RNBB7148; Sigma-
Aldrich, Irvine, UK) supplemented with 10 mM HEPES, 100 IU/ml penicillin, 100 
μg/ml streptomycin, 2 mM L-glutamine (Sigma-Aldrich, Irvine, UK), and 10 % 
foetal bovine serum (FBS). Normally, the B cell preparation was 95 % pure 
(CD19+), with less than 0.5 % CD3+ (T cells) and CD14+ (monocytes). 
5.2.2.4. Treatment of cell cultures with CSE or nicotine  
Unfractionated PBMCs and purified B cells were suspended in complete RPMI 
1640 medium and cultured in 24-well microtitre culture plates (Costar, High 
Wycombe, UK). Two ml of cell suspension was added to each well (2  106 
cells/well). Cells were stimulated with IL-4 (100 U/ml), anti-CD40 mAb (1 mg/ 
ml), and with or without pokeweed mitogen. Some wells were treated with 1 % or 
3 % concentrations of CSE. Nicotine (N3876, Sigma-Aldrich, Irvine, UK) was 
added at final concentrations ranging from 12–200 μg/ml to assess the effects of 
this important constituent of cigarettes on B cells, and some wells were incubated 
with an equal amount of complete medium as a negative control. Cultures were 
routinely maintained at 37 ºC in a 5 % CO2 humidified atmosphere for up to 8 days. 
Then, the supernatants were harvested by centrifugation at 400 x g for 10 min at 4 
ºC. Cell-free supernatants was stored at -20 ºC until aliquots were used for IgG, 
IgM, IgA, and IgD determinations. 
5.2.2.5. Preparation of CSE 
A special technique was used to extract the components of cigarettes. To 
accomplish this, Marlboro Red cigarettes were prepared first by cutting off the 
filters, and the cigarettes were placed into one side of an in-house prepared smoking 
apparatus. The second side of the apparatus was attached to a 50 ml syringe, and 
the third side was attached to a tube containing 10 ml phenol red-free RPMI 
medium (Sigma-Aldrich, Irvine, UK). The extraction was done by drawing 
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cigarette smoke into the syringe and then bubbling it into the medium until the 
entire cigarette was consumed (Figure 5.1). Then, the medium was mixed with the 
smoke and filtered with a 0.45 µm filter. Subsequently, from this mixture, 5 serial 
dilutions were prepared in 5 Eppendorf tubes, and their absorbance were measured 
using a NanoDrop ND-1000 spectrophotometer. Then, a standard curve was 
generated, and the tube with an absorbance of 0.15 was chosen and considered as 
100 %. Finally, the CSE with a concentration of 1 % or 3 % was used to treat the 
cells (Figure 5.2).  
 
Figure 5.1: Preparation of CSE.  
A specialised smoking apparatus was set up: the cigarette was located on one side, 
the second side was connected to a 50 ml syringe, and the third side was contained 
a tube containing 10 ml phenol red-free RPMI medium (Sigma-Aldrich, Irvine, 
UK). The flow between the three connections was controlled by a tap, so the 
cigarette smoke could be into the syringe, and then the direction of the tap changed 
to allow the smoke to be bubbled s into the medium. The process was repeated until 
the entire cigarette was consumed. 
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Figure 5.2: Using a NanoDrop spectrophotometer to analyse CSE absorbance 
in a standard curve.  
The standard curve was generated after determining the absorbance of known 
concentrations (serial dilutions) of CSE that were extracted in the lab. One 
Marlboro Red cigarette was used each time for the extraction, during which the 
smoke was bubbled into phenol red-free medium. Serial dilutions of the CSE were 
prepared. Then, a NanoDrop (ND1000) spectrophotometer was used to measure the 
absorbance values. From the standard curve, it was possible to estimate the 
concentration equal to an absorbance of 0.15, which usually ranged from a 20–25 
% concentration of the total extract. 
 
5.2.2.6. Determination of Ig levels in cell-free supernatants 
Cell-free supernatants from PBMC and B cell cultures were used to measure the 
levels of IgG, IgM, IgA, and IgD. The ELISA technique discussed above (chapter 
2) was used to generate standard curves, and the samples were analysed after a 1:10 
dilution in sample diluent. 
5.2.2.7. Statistical analysis 
Statistical analysis was performed using Prism 6 software. The median values of 
the three groups (treated samples with 3 % CSE, treated samples with nicotine, and 
untreated samples) was compared to that of control-group samples that were treated 
only with stimulators, using the analysis of variance test. 
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5.3. Results 
As shown in Figures 5.3 and 5.4, when supernatants were harvested from PBMC 
and B-cell cultures, the samples treated with 3 % CSE or nicotine showed lower 
IgG, IgM, and IgA concentrations, compared with the group treated only with 
stimulators (control group), IgD was not detected in these samples. By using 
Dunnett's multiple comparisons test for samples collected from PBMCs the results 
showed that IgG levels (Figure 5.3) were significantly lower in samples treated with 
CSE (P  0.05) or nicotine (P  0.05), and in the non-treated samples (P  0.05), 
compared with the stimulated control group. Also, IgM levels (Figure 5.2) were 
significantly lower in samples treated with CSE (P  0.0001), or nicotine (P  
0.0001), and in the non-treated samples (P  0.0001), compared with the stimulated 
control group. IgA appeared to be lower in the treated samples, but there were no 
significant differences between the groups.  
 
 
  
Figure 5.3: Stimulated human PBMCs were incubated for 8 days in the 
presence of anti-CD40, IL-4, PWM, 3 % CSE, or nicotine.  
IgG, IgM, and IgA were detected in the supernatants by performing an ELISA. a) 
IgG levels were lower in samples treated with CSE or nicotine, compared with 
samples treated only with stimulators. b) IgM levels were lower in samples treated 
with CSE or nicotine, compared with samples treated only with stimulators. c) IgA 
levels were lower in samples treated with CSE or nicotine, compared with samples 
treated only with stimulators. 
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Figure 5.4: Stimulated human B cells were incubated for 8 days in the presence 
of anti-CD40, IL-4, PWM, 3 % CSE, or nicotine.  
IgG, IgM, and IgA were detected in the supernatants by performing an ELISA. a) 
IgG levels were lower in samples treated with CSE or nicotine, compared with 
samples treated only with stimulators. b) IgM levels were lower in samples treated 
with CSE or nicotine, compared with samples treated only with stimulators. c) IgA 
levels were lower in samples treated with CSE or nicotine, compared with samples 
treated only with stimulators. 
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5.4. Discussion 
To our knowledge, this is one of the first studies to concentrate on the effects of 
CSE/nicotine on the production of Ig from human cells in vitro. In this study, we 
showed that CSE and nicotine, as one of the most important toxic components in 
CSE, suppressed the production of IgM, IgG, and IgA in both PBMCs and purified 
B cells, which were treated with IL-4, pokeweed mitogen, and anti-CD40 as 
stimulators. Our results were in agreement with those of another report of 
suppressed Ig production by some toxic components when mouse B cells were 
treated with the aryl hydrocarbon receptor (AhR) agonist 2-(1-H-indole-3-
carbonyl)-thiazole-4-carboxylic acid methyl ester in the presence of IL-4 and anti-
CD40 [233]. The molecular mechanism of how AhR suppress B cell differentiation 
into secreting plasma cells is not fully understood. It has been reported that B cell 
suppression could occur via transcriptional regulators of the gene network that 
controls the differentiation of B cells into plasma cells [233].  Moreover, it was also 
reported that immune cells express nicotinic receptors; macrophage nicotinic 
receptors can control the production of pro-inflammatory cytokines, and in T 
lymphocytes, a deficiency of cell activation was correlated with nicotine activity. 
Shock et al. (2003) found that nicotinic receptors in the form of nicotinic 
acetylcholine receptors were expressed in B lymphocyte-derived cell lines, and the 
existence of these receptors was implicated in both the pre-immune state and the 
activation of B lymphocytes, possibly through mediating signalling through the co-
stimulatory molecule CD40, which could contribute to immune depression in 
cigarette smokers [72-74].  
5.5. Conclusions 
Our results showed that CS had direct effects on the production of 
immunoglobulins, and it led to inhibition of the secretion of IgG, IgM and IgA from 
B-cells. Unfortunately, it was only possible to perform a limited number of 
experiments on the effects of CS and nicotine on antibody production in vitro in the 
context of this study, as shown in figures 5.2 and 5.3; it is therefore clear that further 
experiments are needed in the future to confirm the results presented here.  
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6. General Discussion 
The aim of this study was first to investigate the effects of cigarette smoke on Ig 
class expression in the oral cavity and systemically through measuring the 
concentrations of different Ig classes in saliva and serum specimens in healthy 
smoking and non-smoking subjects, using a highly sensitive antibody microarray 
technique that was developed in this study, and subsequently to study the 
underlying mechanism of action in vitro on B cell Ig secretion. We applied our 
optimized and validated antibody microarray platform to the sera and saliva from 
healthy smokers and non-smoker subjects. The results of this study revealed the 
significant differences between Ig classes between smokers and non-smokers in 
serum and saliva samples. Thus, these alterations in Ig levels could contribute to 
inflammation and disease in smokers. In fact, previous studies have shown that 
smokers have up to 10-20 % lower serum IgA, IgG and IgM levels than non-
smokers [1]. However, another study showed that there was higher IgM levels in 
the serum of smokers than non-smokers [126]. It has also been shown that salivary 
IgA levels decrease 7 days after stopping smoking, but they return to normal levels 
two weeks after smoking cessation [1, 234]. In addition, Bouvet et al. (2002) 
reported that sIgA, which is a crucial Ig class produced in human secretions at 
luminal sites involved in oral, gastrointestinal, and respiratory secretions, is 
prompted after antigen (Ag) translocation from the lumen to mucosa-associated 
lymphoid tissue. However, IgG in secretions is derived from the serum or mucosa, 
and increased IgG classes at the mucosal surface could be a defensive response. 
These findings have indicated that tobacco smoke affects both systemic and 
mucosal immunity with fluctuations occurring in mucosal and systemic antibody 
production, which enhances the probability of progression of respiratory disease [1, 
219].  
In the current study, serum and saliva IgG levels were lower in smokers than in 
non-smoker subjects. These findings are consistent with the suppressive effects of 
the toxic components of CS on B cells leading to impaired humoral immune 
responses. We observed increased IgM levels in the serum samples of smokers, 
compared with those measured in non-smoker subjects. This result may reflect the 
crucial role of IgM in neutralizing the toxic components in cigarette smoke. 
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Furthermore, the increase in systemic/circulating IgM levels at the same time as a 
decrease in systemic IgG levels may indicate that components of cigarette smoke 
that enter the blood stream and infiltrate the systemic secondary lymphoid tissues 
(e.g. lymph nodes and spleen) either suppress B cell class switching from IgM to 
IgG production and/or are selectively toxic to memory B cells compared to naïve B 
cells. By contrast, IgM levels were lower in saliva samples from smokers than non-
smoker subjects, which could have been due to the compensatory mechanisms 
between IgM and IgA since the results showed higher IgA levels in the saliva (as 
well as the serum) of smokers. These results are consistent with cigarette smoke 
being a significant cause of inflammation in the respiratory mucosa that is 
manifested through increasing IgA levels, resulting from exaggerated mucosal 
immune responses in smokers and more class switching to IgA.  This offers an 
alternative explanation, to that given above, for the effects of CS on Ig class 
switching: rather than inhibiting all class switching in IgM+ B cells, the effect of CS 
components may be to polarise switching away from IgG and towards IgA. One 
explanation for this could be the effect of CS on T cells and the cytokines they 
produce in the context of the regulation of Ig class switching.  The Th1 cytokine 
IFN- promotes IgG production, whereas the Th2/Treg cytokines IL-5 and TGF- 
promote IgA production. It would therefore be interesting to investigate the effects 
of CS on these T cell subsets. Indeed, our group has preliminary evidence that 
shows raised median levels of TGF- relative to IFN- IL-4 and IL-10 in smokers 
compared to non-smokers and ex-smokers (Figure 6.1) [235]. In terms of TGF- 
there are different studies that have reported an inducing effect of CS on the 
production of TGF- Li et al. (2000), found that, in an animal model, after 3 months 
of smoke exposure TGF- levels were increased significantly compared to the 
normal control, which means this could be considered as one of the mechanisms 
for smoking-induced chronic bronchitis and emphysema [236]. Similar evidence 
comes from Mortaz et al. (2011), which showed that CS stimulates the production 
TGF- in vitro [237]. Moreover, a study in the Chinese population (2013) 
emphasized that there was an important role of the TGF- signalling pathway in 
colorectal cancer, and that was induced with smoking [238]. In terms of IFN- 
Ouyang et al. (2000) indicated that there were inhibitory effects of CS on the 
production of IFN- and IL2 in human PBMC treated samples [239].  
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IgD levels in the serum samples were lower in smokers compared with non-
smokers, and not significantly different between smokers and non-smokers in the 
saliva samples. Studies have shown that IgD has an important role in protecting the 
upper respiratory tract. It is known that human IgM-IgD+ B cells are uncommon in 
peripheral blood, but they make up 20–25 % of the human upper respiratory tract 
mucosal B cells. These cells are located in the tonsils, nasal cavities, lachrymal 
glands and salivary glands, however they are seldom identified in non-respiratory 
mucosal tract locations [240, 241]. Secreted IgD contributes to mucosal immunity 
and can bind to microbial virulence factors as well as pathogenic respiratory 
bacteria and viruses [58]. The number of IgD-producing B cells in respiratory 
mucosa is raised in patients suffering from IgA deficiency [241]. Also, secreted IgD 
activates unknown receptors on various innate immune cells, and previous studies 
have shown that IgD binds with myeloid cells and T cells [58]. Recent studies have 
shown that IgD binds to specific receptors on basophils, mast cells and, to a minor 
degree, to monocytes, neutrophils and myeloid dendritic cells [241, 242]. 
 
Figure 6.1: Graph of the levels of circulating cytokines in smokers and non-
smokers.  
The results showed that TGF- levels in smokers were higher than in non-smokers, 
which may relate to the higher level of IgA in smoking subjects. This figure has 
been adapted from Selvarajah et al.  [235].  
Overall, our results support the concept that cigarette smoke has modulatory effects 
on both systemic and mucosal humoral immunity leading to alterations of B cell 
Circulating cytokines in non-smokers and smokers that promote 
 
 production of IgG (IFN-g / IL-4 / IL-10) or IgA (TGF-b) 
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secretions. 
The effects of CS may be partly explained by the fact that it contains numerous 
oxidants that are capable of interacting with numerous biomolecules, including 
DNA, RNA, lipids, proteins, dietary antioxidants, and numerous endogenously 
synthesized biomolecules, such as glutathione [1, 243, 244]. Therefore, exposure to 
CS is considered to be a key source of cellular oxidative stress that results in lung 
inflammation [1, 245]. Oxidative stress can be described as an increased exposure 
to oxidants with a decreased anti-oxidant efficiency. Two main phases are 
recognized in CS: a tar phase and a gas phase; both phases are rich in oxygen-
centred, carbon-centred, and nitrogen-centred free radicals and non-radical 
oxidants. These include various compounds that can cause increased generation of 
various reactive oxygen species (ROS) such as superoxide (O·-), hydrogen peroxide 
(H2O2), and hydroxyl (OH
-) and peroxyl (ROO·) radicals [1, 246]. These ROS can 
stimulate oxidative damage in the form of lipid peroxidation. Durak et al. (2002) 
showed that smoking generates a significant oxidant load in erythrocytes by 
increasing production of malondialdehyde, which is a marker of lipid peroxidation 
and oxidative stress. In turn the toxic free radicals and oxidants in CS cause 
detrimental reactions with unsaturated fatty acids and several other oxidation-
sensitive molecules, moreover, CS contains copper and iron elements, which 
stimulate hydroxyl radical production [247]. The oxidative stresses carry out crucial 
functions in inflammatory responses to CS, and inflammation itself stimulates 
oxidative stress in the lungs, also gene polymorphisms can function as 
inflammatory mediators or antioxidant genes [1, 248]. In addition, other research 
found that oxidants can activate NF-κB, which plays an essential role in regulating 
the expression of inflammatory genes stimulated by CS [1, 249]. Furthermore, 
oxidative stress can activate regulatory components such as nuclear factor (NF-κB) 
DNA-binding activity, which can regulate the expression of several cytokines such 
as IL-6 and IL-8 [250]. NF-κB can also induce activator protein-1 expression, 
which can control various inflammatory genes that are overexpressed in response 
to CS [1, 251]. Therefore, researchers conclude that there are a number of 
mechanisms working together to explain how diseases are associated with smoking. 
To understand the mechanism of action of CS on B cells, and whether these effects 
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produce biological consequences or not, the final part of our study involved 
preliminary experiments on the effects of CSE, especially nicotine as a major toxic 
component of CS, on B cell secretions in vitro. The levels of IgG, IgM and IgA in 
the supernatants from PBMCs and purified B cells were analysed. 
Interestingly, the results showed that reduced production of all the Ig classes 
occurred when the cells were treated directly with total CSE or nicotine alone 
compared with that observed in control cells. Therefore, our results indicated that 
CS affected the activation of B cells in either the presence or absence of other 
immune cells, which was shown by the levels of Ig classes decreasing in both 
PBMC and the purified B cell supernatants, with the latter indicating that the effect 
was not necessarily T cell-dependent.  Thus, the experiments indicate that CS and 
nicotine can have direct suppressive effects on B cells, although effects on T cells 
and antigen presenting cells, which would also indirectly affect B cell functions, 
are not excluded. These findings agreed with those from other studies, where 
nicotine was considered a main immunosuppressive constituent of CS, as chronic 
nicotine treatment resulted in decreased antibody production [1, 186, 252]. 
Moreover, it has been demonstrated that alveolar macrophages in smokers show 
reduced function as antigen-presenting cells [253]. This outcome may ultimately 
result in impaired T cell function, and, consequently, decreased humoral immune 
responses. 
Our preliminary finding that CS and nicotine suppress production of all the Ig 
classes examined (IgG, IgM and IgA) is different from our findings in smokers, 
particularly for IgA, which was elevated in both the serum and saliva of the 
smokers.  This suggests that the effects of CS in vivo are complex and are not fully 
replicated by our in vitro model.   
 6.1. Conclusions and future work 
In conclusion, this study involved the use of specific reagents for an antibody 
microarray and many experiments were performed to ensure the validity and 
reliability of our method, which resulted in the development of a new antibody 
microarray protocol, using a specific blocking buffer, and capture and detection 
antibodies. The results of this study demonstrated significant differences in Ig levels 
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between smokers and non-smoker subjects. The mechanism of the decreased IgG 
concentrations in smokers may be due, at least in part, to smoking reducing the 
activation of existing memory B cells, or lack of appropriate help from T cells. The 
increased levels of IgM in smokers’ blood could be due to CS constituents blocking 
class switching or enhancing the activation of naïve B cells. Regarding the 
increased IgA production in smokers, IgA plays a crucial role in inflammation, 
especially in lung disease, and our results are in agreement with other studies that 
have shown increased class switching towards IgA in healthy smokers, whereas 
studies found that COPD smokers had increased switching towards IgG [130]. 
Brandsma et al. (2009) observed a negative correlation between B cells and Treg 
cells, and they reported Tregs can inhibit B cells, with increased class switching of 
memory B cells to IgA [254].  
One of the possible mechanisms can be summarized as follows: CS is a highly-
concentrated source of ROS which interacts with body biomolecules through 
numerous mechanisms, depending on the amount and way of smoking, and the 
susceptibility of smokers. These interactions might change the humoral immunity, 
and then by direct or indirect processes cause inflammation and increased incidence 
of multiple diseases.  
Regarding the in vitro work that focused on the influence of CSE/nicotine on 
PBMC and B cells, a protocol was developed to determine the concentrations of 
cells, stimulators, and CSE. The results showed a drop in the secretion of Ig classes 
examined in cells exposed to CSE/nicotine, compared to that observed in the 
control groups. This may be explained by the fact B cells express nicotinic receptors 
that recognize and bind cigarette toxins and result in impaired B cell proliferation, 
and consequently causing decreased Ig production [72, 73]. 
Finally, the results of this study confirmed the impact of CS on both systemic and 
mucosal immunity, with alterations shown in mucosal and systemic antibody 
production, which promote inflammation and, consequently, the incidence of 
respiratory disorders. In addition, CS exposure can affect the proliferation of B-
cells through direct or indirect pathways.  
Chapter 6                                                                                        General Discussion 
125 
 
Certain limitations are associated with this study. For example, this study was 
performed with men only; further studies should include female populations. In 
addition, in this study, we used a questionnaire to assess the smoking status of the 
patients, which is a subjective measure. Other, more accurate assessments can be 
used in the future. A small number of samples were used for the in vitro 
experiments. The use of a larger sample size could engender greater confidence in 
the results. In conclusion, the current observations suggested that cigarette smoking 
is associated with altered B cell functions and, consequently, changes in Ig 
production.  
The results of this thesis suggest several interesting avenues of investigation that 
could consolidate the results of this study in the future:  
Antibody microarray: The reagents that were used in our developed antibody 
microarray were designed to investigate large numbers of samples in very small 
quantities because of the numerous experiments needed to test the accuracy of these 
components and ensure the precision of the results. Our protocol can be used in the 
future as an indicator of early changes in Ig levels, to study the incidence of multiple 
diseases, and potentially to monitor diseases in their earliest stages. 
Stability of the printing on the slides: An important parameter that should be 
investigated is how long the capture antibody can remain stable on the poly-L-
lysine slides, and how to maximise this stability.  This would then facilitate the bulk 
production and storage of slides coated with the capture antibody for future use. 
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